WARNING: SEVERE MYELOSUPPRESSION
- Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 [see Contraindications (4)].
- Monitor for neutropenia, which may be severe and result in infection or sepsis [see Warnings and Precautions (5.1, 5.3)].
- Perform frequent complete blood cell counts on all patients receiving ABRAXANE [see Warnings and Precautions (5.1, 5.3)]. WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning.
- Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3. (4)
- Monitor for neutropenia, which may be severe and result in infection or sepsis. (5.1, 5.3)
- Perform frequent complete blood cell counts on all patients receiving ABRAXANE. (5.1, 5.3)
Use: Labeled indications
- Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
- Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ABRAXANE is a microtubule inhibitor indicated for the treatment of:
- Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1)
- Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2)
- Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3) 1.1 Metastatic Breast Cancer ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. 1.2 Non-Small Cell Lung Cancer ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. 1.3 Adenocarcinoma of the Pancreas ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Contraindications
4 CONTRAINDICATIONS ABRAXANE is contraindicated in patients with: • Baseline neutrophil counts of < 1,500 cells/mm 3 [see Warnings and Precautions (5.1)] • A history of severe hypersensitivity reactions to ABRAXANE [see Warnings and Precautions (5.5)] • Neutrophil counts of < 1,500 cells/mm 3. (4) • Severe hypersensitivity reactions to ABRAXANE. (4)
US FDA labelDosing: Adult
- • Do not substitute ABRAXANE for other paclitaxel products. (2.1)
- • Extravasation: Closely monitor the infusion site for extravasation and infiltration. (2.1)
- • Metastatic Breast Cancer (MBC): Recommended dosage of ABRAXANE is 260 mg/m 2 intravenously over 30 minutes every 3 weeks. (2. 2) • Non-Small Cell Lung Cancer (NSCLC): Recommended dosage of ABRAXANE is 100 mg/m 2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE. (2.3)
- • Adenocarcinoma of the Pancreas: Recommended dosage of ABRAXANE is 125 mg/m 2 intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE. (2.4)
- • Use in Patients with Hepatic Impairment: ABRAXANE is not recommended for use in patients with AST > 10 × ULN; or bilirubin > 5 × ULN or with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For MBC or NSCLC, reduce starting dose in patients with moderate to severe hepatic impairment. (2.5)
- • Dose Reductions for Adverse Reactions: Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities. (2.6)
2.1 Important Administration Instructions DO NOT
2.1 Important Administration Instructions DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS. ABRAXANE has different dosage and administration instructions from other paclitaxel products. Closely monitor the infusion site for extravasation or drug infiltration during administration. Limiting the infusion of ABRAXANE to 30 minutes may reduce the risk of infusion-related reactions [see Adverse Reactions (6.2)].
Consider premedication in patients who have had prior hypersensitivity reactions to ABRAXANE. Do not re-challenge patients who experience a severe hypersensitivity reaction to ABRAXANE [see Contraindications (4) and Warnings and Precautions (5.5)].
2.2 Recommended Dosage for Metastatic Breast Cancer
2.2 Recommended Dosage for Metastatic Breast Cancer After failure of combination chemotherapy for metastatic breast cancer or relapse within 6 months of adjuvant chemotherapy, the recommended regimen for ABRAXANE is 260 mg/m 2 administered intravenously over 30 minutes every 3 weeks.
2.3 Recommended Dosage for Non-Small Cell Lung Cancer
2.3 Recommended Dosage for Non-Small Cell Lung Cancer The recommended dose of ABRAXANE is 100 mg/m 2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE [see Clinical Studies (14.2)].
2.4 Recommended Dosage for Adenocarcinoma of the Pancreas
2.4 Recommended Dosage for Adenocarcinoma of the Pancreas The recommended dose of ABRAXANE is 125 mg/m 2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. Administer gemcitabine immediately after ABRAXANE on Days 1, 8, and 15 of each 28-day cycle [see Clinical Studies (14.3)].
2.5 Dosage Modifications for Hepatic Impairment
2.5 Dosage Modifications for Hepatic Impairment For patients with moderate or severe hepatic impairment, reduce the starting dose of ABRAXANE as shown in Table 1. Table 1: Recommendations for Starting Dose in Patients with Moderate and Severe Hepatic Impairment AST = Aspartate Aminotransferase; MBC = Metastatic Breast Cancer; NSCLC = Non-Small Cell Lung Cancer; ULN = Upper limit of normal. a Dosage recommendations are for the first course of therapy.
The need for further dose adjustments in subsequent courses should be based on individual tolerance. b A dose increase to 260 mg/m 2 for patients with metastatic breast cancer or 100 mg/m 2 for patients with non-small cell lung cancer in subsequent courses should be considered if the patient tolerates the reduced dose for two cycles. c Patients with bilirubin levels above the upper limit of normal were excluded from clinical trials for pancreatic or lung cancer. AST Levels Bilirubin Levels ABRAXANE Dose a MBC NSCLC c Adenocarcinoma of Pancreas c Moderate < 10 x ULN AND > 1.5 to ≤ 3 x ULN 200 mg/m 2 b 80 mg/m 2 b not recommended Severe < 10 x ULN AND > 3 to ≤ 5 x ULN 200 mg/m 2 b 80 mg/m 2 b not recommended > 10 x ULN OR > 5 x ULN not recommended not recommended not recommended
2.6 Dosage Modifications for Adverse Reactions Metastatic Breast Cancer
2.6 Dosage Modifications for Adverse Reactions Metastatic Breast Cancer Patients who experience severe neutropenia (neutrophils less than 500 cells/mm 3 for a week or longer) or severe sensory neuropathy during ABRAXANE therapy should have dosage reduced to 220 mg/m 2 for subsequent courses of ABRAXANE. For recurrence of severe neutropenia or severe sensory neuropathy, additional dose reduction should be made to 180 mg/m 2.
For Grade 3 sensory neuropathy hold treatment until resolution to Grade 1 or 2, followed by a dose reduction for all subsequent courses of ABRAXANE [see Contraindications (4), Warnings and Precautions (5.1, 5.2) and Adverse Reactions (6.1)]. Non-Small Cell Lung Cancer
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm 3 and platelet count is at least 100,000 cells/mm 3 [see Contraindications (4), Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
- In patients who develop severe neutropenia or thrombocytopenia withhold treatment until counts recover to an absolute neutrophil count of at least 1500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an absolute neutrophil count of at least 500 cells/mm 3 and platelet count of at least 50,000 cells/mm 3 on Days 8 or 15 of the cycle. Upon resumption of dosing, permanently reduce ABRAXANE and carboplatin doses as outlined in Table 2.
- Withhold ABRAXANE for Grade 3-4 peripheral neuropathy. Resume ABRAXANE and carboplatin at reduced doses (see Table 2) when peripheral neuropathy improves to Grade 1 or completely resolves [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]. Table 2: Permanent Dose Reductions for Hematologic and Neurologic Adverse Reactions in NSCLC Adverse Reaction Occurrence Weekly ABRAXANE Dose (mg/m 2) Every 3-Week Carboplatin Dose (AUC mg•min/mL) Neutropenic Fever (ANC less than 500/mm 3 with fever >38°C) OR Delay of next cycle by more than 7 days for ANC less than 1500/mm 3 OR ANC less than 500/mm 3 for more than 7 days First 75 4.5 Second 50 3 Third Discontinue Treatment Platelet count less than 50,000/mm 3 First 75 4.5 Second Discontinue Treatment Severe sensory Neuropathy – Grade 3 or 4 First 75 4.5 Second 50 3 Third Discontinue Treatment Adenocarcinoma of the Pancreas Dose level reductions for patients with adenocarcinoma of the pancreas, as referenced in Tables 4 and 5, are provided in Table 3. Table 3: Dose Level Reductions for Patients with Adenocarcinoma of the Pancreas Dose Level ABRAXANE (mg/m 2) Gemcitabine (mg/m 2) Full dose 125 1000 1 st dose reduction 100 800 2 nd dose reduction 75 600 If additional dose reduction required Discontinue Discontinue Recommended dose modifications for neutropenia and thrombocytopenia for patients with adenocarcinoma of the pancreas are provided in Table 4. Table 4: Dose Recommendation and Modifications for Neutropenia and/or Thrombocytopenia at the Start of a Cycle or within a Cycle for Patients with Adenocarcinoma of the Pancreas ANC = Absolute Neutrophil Count Cycle Day ANC (cells/mm 3) Platelet count (cells/mm 3) ABRAXANE / Gemcitabine Day 1 < 1500 OR < 100,000 Delay doses until recovery Day 8 500 to < 1000 OR 50,000 to < 75,000 Reduce 1 dose level < 500 OR < 50,000 Withhold doses Day 15: If Day 8 doses were reduced or given without modification: 500 to < 1000 OR 50,000 to < 75,000 Reduce 1 dose level from Day 8 < 500 OR < 50,000 Withhold doses Day 15: If Day 8 doses were withheld: ≥ 1000 OR ≥ 75,000 Reduce 1 dose level from Day 1 500 to < 1000 OR 50,000 to < 75,000 Reduce 2 dose levels from Day 1 < 500 OR < 50,000 Withhold doses Recommended dose modifications for other adverse reactions in patients with adenocarcinoma of the pancreas are provided in Table 5. Table 5: Dose Modifications for Other Adverse Reactions in Patients with Adenocarcinoma of the Pancreas Adverse Reaction ABRAXANE Gemcitabine Febrile Neutropenia: Grade 3 or 4 Withhold until fever resolves and ANC ≥ 1500; resume at next lower dose level Peripheral Neuropathy: Grade 3 or 4 Withhold until improves to ≤ Grade 1; resume at next lower dose level No dose reduction Cutaneous Toxicity: Grade 2 or 3 Reduce to next lower dose level; discontinue treatment if toxicity persists Gastrointestinal Toxicity: Grade 3 mucositis or diarrhea Withhold until improves to ≤ Grade 1; resume at next lower dose level
2.7 Preparation for Intravenous Administration
2.7 Preparation for Intravenous Administration ABRAXANE is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 The use of gloves is recommended. If ABRAXANE (lyophilized cake or reconstituted suspension) contacts the skin, wash the skin immediately and thoroughly with soap and water. Following topical exposure to paclitaxel, events may include tingling, burning, and redness.
If ABRAXANE contacts mucous membranes, the membranes should be flushed thoroughly with water. ABRAXANE is supplied as a sterile lyophilized powder for reconstitution before use. Read the entire preparation instructions prior to reconstitution. 1. Aseptically, reconstitute each vial by injecting 20 mL of 0.9% Sodium Chloride Injection, USP. 2.
Slowly inject the 20 mL of 0.9% Sodium Chloride Injection, USP, over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the INSIDE WALL OF THE VIAL. 3. DO NOT INJECT the 0.9% Sodium Chloride Injection, USP, directly onto the lyophilized cake as this will result in foaming. 4. Once the injection is complete, allow the vial to sit for a minimum of 5 minutes to ensure proper wetting of the lyophilized cake/powder. 5.
Gently swirl and/or invert the vial slowly for at least 2 minutes until complete dissolution of any cake/powder occurs. Avoid generation of foam. 6. If foaming or clumping occurs, stand solution for at least 15 minutes until foam subsides. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel. The reconstituted suspension should be milky and homogenous without visible particulates.
If particulates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use. Discard the reconstituted suspension if precipitates are observed. Discard any unused portion. Calculate the exact total dosing volume of 5 mg/mL suspension required for the patient and slowly withdraw the dosing volume of the reconstituted suspension from the vial(s) into a syringe: Dosing volume (mL)=Total dose (mg)/5 (mg/mL).
Inject the appropriate amount of reconstituted ABRAXANE into an empty, sterile intravenous bag [plasticized polyvinyl chloride (PVC) containers, PVC or non-PVC type intravenous bag]. The use of specialized DEHP-free solution containers or administration sets is not necessary to prepare or administer ABRAXANE infusions. The use of medical devices containing silicone oil as a lubricant (i.e., syringes and intravenous bags) to reconstitute and administer ABRAXANE may result in the formation of proteinaceous strands.
Visually inspect the reconstituted ABRAXANE suspension in the intravenous bag prior to administration. Discard the reconstituted suspension if proteinaceous strands, particulate matter, or discoloration are observed. Slowly inject the 20 mL of 0.9% Sodium Chloride Injection, USP, over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the INSIDE WALL OF THE VIAL.
2.8 Stability
2.8 Stability Unopened vials of ABRAXANE are stable until the date indicated on the package when stored between 20°C to 25°C (68°F to 77°F) in the original package. Neither freezing nor refrigeration adversely affects the stability of the product. Stability of Reconstituted Suspension in the Vial Reconstituted ABRAXANE in the vial should be used immediately, but may be refrigerated at 2°C to 8°C (36°F to 46°F) for a maximum of 24 hours if necessary.
If not used immediately, each vial of reconstituted suspension should be replaced in the original carton to protect it from bright light. Discard any unused portion. Stability of Reconstituted Suspension in the Infusion Bag The suspension for infusion when prepared as recommended in an infusion bag should be used immediately, but may be refrigerated at 2°C to 8°C (36°F to 46°F) and protected from bright light for a maximum of 24 hours.
The total combined refrigerated storage time of reconstituted ABRAXANE in the vial and in the infusion bag is 24 hours. This may be followed by storage in the infusion bag at ambient temperature (approximately 25°C) and lighting conditions for a maximum of 4 hours. Discard any unused portion.
Dosing: Altered kidney function
8.6 Renal Impairment No adjustment of the starting ABRAXANE dose is required for patients with mild to moderate renal impairment (estimated creatinine clearance 30 to <90 mL/min) [see Clinical Pharmacology (12.3)]. There are insufficient data to permit dosage recommendations in patients with severe renal impairment or end stage renal disease (estimated creatinine clearance <30 mL/min).
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment No adjustment of the starting ABRAXANE dose is required for patients with mild hepatic impairment (total bilirubin > ULN and ≤ 1.5 x ULN and aspartate aminotransferase [AST] ≤ 10 x ULN). Reduce ABRAXANE starting dose in patients with moderate to severe hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
ABRAXANE is not recommended for use in patients with total bilirubin > 5 x ULN or AST > 10 x ULN [see Dosage and Administration (2.5), Warnings and Precautions (5.6), and Clinical Pharmacology (12.3)]. ABRAXANE is not recommended for use in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment [see Dosage and Administration (2.5)].
2.5 Dosage Modifications for Hepatic Impairment For patients with moderate or severe hepatic impairment, reduce the starting dose of ABRAXANE as shown in Table 1. Table 1: Recommendations for Starting Dose in Patients with Moderate and Severe Hepatic Impairment AST = Aspartate Aminotransferase; MBC = Metastatic Breast Cancer; NSCLC = Non-Small Cell Lung Cancer; ULN = Upper limit of normal. a Dosage recommendations are for the first course of therapy.
The need for further dose adjustments in subsequent courses should be based on individual tolerance. b A dose increase to 260 mg/m 2 for patients with metastatic breast cancer or 100 mg/m 2 for patients with non-small cell lung cancer in subsequent courses should be considered if the patient tolerates the reduced dose for two cycles. c Patients with bilirubin levels above the upper limit of normal were excluded from clinical trials for pancreatic or lung cancer. AST Levels Bilirubin Levels ABRAXANE Dose a MBC NSCLC c Adenocarcinoma of Pancreas c Moderate < 10 x ULN AND > 1.5 to ≤ 3 x ULN 200 mg/m 2 b 80 mg/m 2 b not recommended Severe < 10 x ULN AND > 3 to ≤ 5 x ULN 200 mg/m 2 b 80 mg/m 2 b not recommended > 10 x ULN OR > 5 x ULN not recommended not recommended not recommended
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Pharmacokinetics, safety, and antitumor activity of ABRAXANE were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors.
The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. No new safety signals were observed in pediatric patients across these studies. Paclitaxel protein-bound exposures normalized by dose were higher in 96 pediatric patients (aged 1.4 to < 17 years) as compared to those in adults.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 229 patients in the randomized study who received ABRAXANE for the treatment of metastatic breast cancer, 13% were at least 65 years of age and < 2% were 75 years or older. This study of ABRAXANE did not include a sufficient number of patients with metastatic breast cancer who were 65 years and older to determine whether they respond differently from younger patients.
A subsequent pooled analysis was conducted in 981 patients receiving ABRAXANE monotherapy for metastatic breast cancer, of which 15% were 65 years of age or older and 2% were 75 years of age or older. A higher incidence of epistaxis, diarrhea, dehydration, fatigue, and peripheral edema was found in patients 65 years of age or older.
Of the 514 patients in the randomized study who received ABRAXANE and carboplatin for the first-line treatment of non-small cell lung cancer, 31% were 65 years or older and 3.5% were 75 years or older. Myelosuppression, peripheral neuropathy, and arthralgia were more frequent in patients 65 years or older compared to patients younger than 65 years old.
No overall difference in effectiveness, as measured by response rates, was observed between patients 65 years or older compared to patients younger than 65 years old. Of the 431 patients in the randomized study who received ABRAXANE and gemcitabine for the first-line treatment of pancreatic adenocarcinoma, 41% were 65 years or older and 10% were 75 years or older.
No overall differences in effectiveness were observed between patients who were 65 years of age or older and younger patients. Diarrhea, decreased appetite, dehydration, and epistaxis were more frequent in patients 65 years or older compared with patients younger than 65 years old. Clinical studies of ABRAXANE did not include sufficient number of patients with pancreatic cancer who were 75 years and older to determine whether they respond differently from younger patients.
Administration
2.1 Important Administration Instructions DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS. ABRAXANE has different dosage and administration instructions from other paclitaxel products. Closely monitor the infusion site for extravasation or drug infiltration during administration. Limiting the infusion of ABRAXANE to 30 minutes may reduce the risk of infusion-related reactions [see Adverse Reactions (6.2) ] . Consider premedication in patients who have had prior hypersensitivity reactions to ABRAXANE. Do not re-challenge patients who experience a severe hypersensitivity reaction to ABRAXANE [see Contraindications (4) and Warnings and Precautions (5.5) ] .
2.7 Preparation for Intravenous Administration ABRAXANE is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 The use of gloves is recommended. If ABRAXANE (lyophilized cake or reconstituted suspension) contacts the skin, wash the skin immediately and thoroughly with soap and water. Following topical exposure to paclitaxel, events may include tingling, burning, and redness. If ABRAXANE contacts mucous membranes, the membranes should be flushed thoroughly with water. ABRAXANE is supplied as a sterile lyophilized powder for reconstitution before use. Read the entire preparation instructions prior to reconstitution. 1. Aseptically, reconstitute each vial by injecting 20 mL of 0.9% Sodium Chloride Injection, USP. 2. Slowly inject the 20 mL of 0.9% Sodium Chloride Injection, USP, over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the INSIDE WALL OF THE VIAL. 3. DO NOT INJECT the 0.9% Sodium Chloride Injection, USP, directly onto the lyophilized cake as this will result in foaming. 4. Once the injection is complete, allow the vial to sit for a minimum of 5 minutes to ensure proper wetting of the lyophilized cake/powder. 5. Gently swirl and/or invert the vial slowly for at least 2 minutes until complete dissolution of any cake/powder occurs. Avoid generation of foam. 6. If foaming or clumping occurs, stand solution for at least 15 minutes until foam subsides. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel. The reconstituted suspension should be milky and homogenous without visible particulates. If particulates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use. Discard the reconstituted suspension if precipitates are observed. Discard any unused portion. Calculate the exact total dosing volume of 5 mg/mL suspension required for the patient and slowly withdraw the dosing volume of the reconstituted suspension from the vial(s) into a syringe: Dosing volume (mL)=Total dose (mg)/5 (mg/mL). Inject the appropriate amount of reconstituted ABRAXANE into an empty, sterile intravenous bag [plasticized polyvinyl chloride (PVC) containers, PVC or non-PVC type intravenous bag]. The use of specialized DEHP-free solution containers or administration sets is not necessary to prepare or administer ABRAXANE infusions. The use of medical devices containing silicone oil as a lubricant (i.e., syringes and intravenous bags) to reconstitute and administer ABRAXANE may result in the formation of proteinaceous strands. Visually inspect the reconstituted ABRAXANE suspension in the intravenous bag prior to administration. Discard the reconstituted suspension if proteinaceous strands, particulate matter, or discoloration are observed. Slowly inject the 20 mL of 0.9% Sodium Chloride Injection, USP, over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the INSIDE WALL OF THE VIAL.
US FDA labelDosage forms
Philippines
- ) solution for injection: 6 mg/mL (100 mg/16. 7 mL, 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (100.2 mg/16.7 mL, 6 mg/mL (260.4 mg/43.4 mL, 6 mg/mL (30 mg/5 mL, 6 mg/mL (300 mg/50 mL, 6 mg/mL (60 mg/10 mL
- ) solution for intravenous infusion: 6 mg/mL ( 100 mg/16. 7 mL, 6 mg/mL (100 mg/16.67 mL, 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (150 mg/25 mL, 6 mg/mL (260 mg/43.3 mL, 6 mg/mL (260 mg/43.4 mL, 6 mg/mL (30 mg/5 mL
- ) solution for iv infusion: 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (260 mg/43.4 mL, 6 mg/mL (30 mg/5 mL, 6 mg/mL (300 mg/50 mL
- ) concentrate solution for iv infusion: 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (260 mg/43.4 mL, 6 mg/mL (30 mg/5 mL
- Lyophilized powder for suspension for iv infusion: 100 mg
- ) concentrate solution for i.v. infusion: 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (260 mg/43.4 mL, 6 mg/mL (30 mg/5 mL
- Solution for injection: 6 mg/mL, 30 mg/5 mL, 100 mg/16.7 mL
- ) concentrate solution for infusion: 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (30 mg/5 mL
- ) concentrate for solution for iv infusion: 6 mg/mL (100 mg/16.7 mL, 6 mg/mL (30 mg/5 mL, 6 mg/mL (300 mg/50 mL
- Solution for i.v. infusion: 6 mg/mL
and 24 more forms; see the products table.
Registered products in the Philippines
151 products registered with the Food and Drug Administration (FDA) Philippines list Paclitaxel as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Pacliatcel (1 product). Products registered under these spellings are included in the table and marked.
All registered products151
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AclitelPaclitaxel | 6 mg / mL (100 mg / 16.7 mL) Solution for Injection (IV Infusion)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 16.7 mL (Net Content) (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited - Rupganj PlantBangladesh | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-12602-03 | Sep 13, 2028 | |
ApexelsinPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion (Protein-bound particles)50 mL-capacity Type I glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Kexing Biopharm Co. Ltd.China | Orange Biotec Inc. | DRP-17881 | Mar 30, 2031 | |
AplitaxPaclitaxel | 6 mg/mL (30 mg/5 mL, 100mg/16.7 mL and 150 mg/25 mL) Concentrate Solution for Injection (IV Infusion) | RxVAT-exempt | Sobhan Oncology Co.Iran | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-11551 | Feb 11, 2031 | |
Axekon 100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip Off Seal Cap x 16.7 mL (Net content) (Box of l's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited - Rupganj PlantBangladesh | Pharmakon Biotec, Inc. | DRP-12602 | Sep 13, 2027 | |
BelcytaxPaclitaxel | 6 mg/mL Solution for Injection (IV Infusion)USP Type I Clear Glass Vial x 5 mL, 16.7 mL, 25 mL and 50 mL (Box of 1's) | RxVAT-exempt | Biolyse Pharma CorporationCanada | Onco Care Pharma CorporationImporter: Belcynor Pharmaceuticals Inc. | DRP-8812-02 | Dec 15, 2026 | |
BravifoPaclitaxel | 6 mg / mL (30 mg / 5 mL) Solution for InfusionType I Clear Glass Vial Sealed with Dark Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip Off Seal Cap x 5 mL (Box of 1's) | RxVAT-exempt | MSN Laboratories Private Limited (Formulations Division)India | Metro Drug, Inc.Importer: Mega Lifesciences Limited, Inc. | DR-XY47844 | Mar 29, 2027 | |
BravifoPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL Type I Clear Glass Vial Sealed with Dark Gray Bromobutyl Rubber Stopper and Yellow Aluminum Flip-Off Seal Cap x 16.7 mL (Net content) (Box of 1's) | RxVAT-exempt | MSN Laboratories Private Limited (Formulations Division)India | Metro Drug, Inc.Importer: Mega Lifesciences Limited, Inc. | DR-XY47845 | Mar 29, 2027 | |
BravifoPaclitaxel | 6 mg/mL (300mg/50mL) Solution for Injection (IV Infusion)Type I Clear Glass Vial Sealed with Dark Gray Bromobutyl Rubber Stopper and Green Aluminum. Flip-Off Seal Cap x 50 mL (Box of 1's) | RxVAT-exempt | MSN Laboratories Private Limited (Formulations Division)India | Metro Drug, Inc.Importer: Mega Lifesciences Limited, Inc. | DR-XY47846 | Mar 29, 2027 | |
BrevixelPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL USP Type I Amber Glass Vial (Net Content 16.7 mL) Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | 2MG IncorporatedImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4751-03 | Sep 26, 2028 | |
BrevixelPaclitaxel | 6 mg/mL (260 mg/43.4 mL) Solution for IV Infusion43.4 mL (net content) in 50 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | 2MG IncorporatedImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4752-01 | Sep 26, 2028 | |
BrevixelPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV Infusion)5 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | 2MG IncorporatedImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4750-03 | Sep 26, 2028 | |
CansurePaclitaxel | 6 mg/mL Solution for Injection (IV)USP Type I Amber Moulded Glass Vial x 5 mL, 16.7 mL, 25 mL and 43.4 mL sealed with aluminum with Blue Flip-off Cap (Box of 1 's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-4844 | Oct 18, 2028 | |
CatalanPaclitaxel | 6 mg/mL Solution for I.V. InfusionUSP Type I clear glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal / (Box of 1's) 5 mL (30 mg/5 mL net content); 20 mL (100 mg/16.7 mL net content); 50 mL (260 mg/43.4 mL net content); 50 mL (300 mg/50.0 mL net content) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10592-03 | Oct 26, 2031 | |
CeltaxPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Intravenous InfusionUSP Type I Clear and colorless glass vial with red flip-off seal x 16.7 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E Medica Inc. | DRP-2241 | Jun 4, 2030 | |
CeltaxPaclitaxel | 6 mg/mL (260 mg/43.3 mL) Solution for Intravenous InfusionUSP Type I Clear and Colorless Glass Vial with Red Flip-Off Seal x 43.3 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E Medica Inc. | DRP-2240 | Jun 4, 2030 | |
CeltaxPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for intravenous InfusionUSP Type I clear and colorless glass vial with red flip-off seal x 5mL (Box of 1's); USP Type I clear and colorless glass vial with red flip-off seal x 25mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E Medica Inc. | DRP-2239 | Feb 9, 2037 | |
ClaxelPaclitaxel | 6 mg/mL (30 mg / 5 mL, 100 mg / 16.7 mL and 300 mg / 50 mL) Concentrate for Solution for I.V. InfusionUSP Type 1 Clear and Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 5 mL, 16.7 mL and 50 mL net content Box of 1's and 10's | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Company LimitedChina | Oncolife Corporation | DRP-15100 | Jun 18, 2031 | |
ClipaxPaclitaxel | 6 mg/mL Concentrate Solution for I.V. Infusion16.7 mL USP Type I Clear Colorless Vial with Butyl Rubber Stopper (Box of 1's) | RxVAT-exempt | Fareva Unterach GmbHAustria | The Cathay Drug Co., Inc.Importer: Sandoz Philippines Corporation | DRP-11497-01 | Apr 5, 2028 | |
ClitaxPaclitaxel | 6 mg/mL Solution for I.V. InfusionUSP Type I clear glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal / (Box of 1's) 5 mL (30 mg/5 mL net content); 20 mL (100 mg/16.7 mL net content); 50 mL (260 mg/43.4 mL net content); 50 mL (300 mg/50.0 mL net content) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10592-02 | Oct 26, 2031 | |
Clitaxsaph-100Paclitaxel | 100mg Lyophilized Powder For (I.V. Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11218 | Feb 15, 2027 | |
Cytax 100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution for IV Infusion20 mL-capacity Type I Clear Tubular Glass Vial with 20 mm Flourotec Stopper and 20 mm Opaque Light Blue Aluminum Flip-off Seal (Box of 1’s) | RxVAT-exempt | Intas Pharmaceutical LimitedIndia | Accord Healthcare Limited -Philippines Branch Offic e | DRP-9083 | Sep 30, 2031 | |
Cytax-30Paclitaxel | 6 mg/mL Concentrate Solution for IV InfusionUSP Type I Clear Tubular Vial with Grey Rubber (Box of 1 Vial x 5 mL) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8275 | Aug 5, 2029 | |
Emitexal-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Intravenous Infusion20 mL USP Type I Clear Glass Vial x 16.7 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8802-03 | Oct 3, 2028 | |
FonkopacPaclitaxel | 6 mg/mL (100 mg/ mL 16.7 mL) Concentrate Solution for Intravenous InfusionType 1 clear glass vial in 16.7 mL (net content) Box of 1's. | RxVAT-exempt | PT FONKO INTERNATIONAL PHARMACEUTICALSIndonesia | Glorious Dexa Mandaya, Inc. | DR-XY46568 | May 20, 2029 | |
FonkopacPaclitaxel | 6mg/ mL (300mg/ 50mL) Concentrate Solution For Intravenous InfusionType 1 Clear Glass Vial in 50mL (net content) (Box of 1's) | RxVAT-exempt | PT Fonko International PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc. | DR-XY46569 | May 20, 2029 | |
Gentaxel-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution for Infusion (IV)20 ml Type 1 Clear Tubular Glass Vial with 20mm Rubber Stopper and 20mm Black Aluminum flip-off Seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8583-01 | Dec 18, 2029 | |
Gentaxel-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution for Infusion (IV)5 mL Type i Clear Moulded Glass Vial sealed with 20 mm Rubber Stopper and 20 mm Black Aluminum Flip-off Seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8582-01 | Dec 18, 2029 | |
GoclitaxPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL USP Type I Amber Glass Vial [Net content 16.7 mL] (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4751-05 | Sep 26, 2028 | |
GoclitaxPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV Infusion)5 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4750-05 | Sep 26, 2028 | |
IntaxelPaclitaxel | 6mg/mL Sterile Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial with Grey Fluorotec Rubber Closure and Aluminum Flip-off Seal x 43.4 mL in 50 mL-capacity Vial, 16.7 mL in 20 mL-capacity Vial and 5 mL in 5 mL-capacity Vial (Box of 1's) | RxVAT-exempt | Fresenius Kabi Oncology LimitedIndia | Fresenius Kabi Philippines, Inc. | DR-XY41771 | Mar 7, 2028 | |
Lexatax-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL USP Type I Amber Glass Vial [Net Content 16.7 mL] (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | D&G PharmaImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4751-01 | Sep 26, 2028 | |
Lexatax-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (I.V. Infusion)5 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | D&G PharmaImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4750-01 | Sep 26, 2028 | |
MaclitaxPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV)Clear glass ampoule x 5mL (Box of 1's) | RxVAT-exempt | Cisen Pharmaceutical Co., Ltd.China | Macropharma Corporation | DRP-15882 | Sep 25, 2029 | |
MaclitaxPaclitaxel | 6 mg/mL (60 mg/10 mL) Solution for Injection (IV)10 mL Glass Ampoule (Box of 1's) | RxVAT-exempt | Cisen Pharmaceutical Co., Ltd.China | Macropharma Corporation | DRP-16002 | Oct 10, 2029 | |
MacrotaxelPaclitaxel | 6 mg/mL (100mg/16.7mL) Solution For Injection (IV Infusion)20 mL Type I Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 16.67 mL (Net content) (Box of l's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Macropharma Corporation | DRP-11496 | Mar 17, 2027 | |
MacrotaxelPaclitaxel | 6 mg/mL (260 mg/43.4 mL) Concentrate for Solution for I.V. Infusion43.4 mL (net content) in a 50 mL capacity USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and non-tear-off aluminum seal with black polypropylene flip-off cap (box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Macropharma Corporation | DRP-13407 | Feb 14, 2028 | |
MacrotaxelPaclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution for IVType I glass vial with bromo butyl rubber stopper, aluminum seal and flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Macropharma Corporation | DRP-15532 | Jul 31, 2029 | |
MedextralPaclitaxel | 6mg/mL (30mg/5mL) Concentrate for Solution for IV InfusionUSP Type I amber molded glass vial x 5mL stoppered with bromo butyl rubber stopper and green flip off seal (Box of 1's and 10's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Medinova Pharmaceutical Inc. | DRP-17378 | Nov 25, 2030 | |
Medtaxel-100Paclitaxel | 6mg/ml (100mg/16.7ml) Concentrate Solution for Infusion (IV)20 ml Type 1 clear tubular glass vial with 20mm rubber stopper and 20mm black aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | APPLIED PHARMACEUTICAL DISTRIBUTION INC.Importer: MEDINOVA PHARMACEUTICAL INC.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8583 | Dec 18, 2029 | |
Medtaxel-30Paclitaxel | 6 mg/mL (30mg/5mL) Concentrate Solution for Infusion (IV)5 ml Type i clear moulded glass vial with 20 mm rubber stopper and 20 mm black aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceuticals, Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8582 | Dec 18, 2029 | |
MitobanPaclitaxel | 6 mg/mL (100.2 mg/16.7 mL) Solution for Injection (IV)USP Type I Clear Glass Vial x 20 mL w/ White Coloured Flip-off Seal Box of 1's | RxVAT-exempt | M/S Adley Formulations Pvt. LtdIndia | ASA LIFE PHILIPPINES LIMITED INC | DRP-5353 | Jun 25, 2029 | |
MitobanPaclitaxel | 6 mg/mL (260.4 mg/43.4 mL) Solution for Injection (IV Infusion)USP Type I clear glass vial with white coloured flip-off seal x 43.4 mL filled in 50 mL (Box of 1’s) | RxVAT-exempt | Adley Formulations Private LimitedIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-4878 | Nov 6, 2028 | |
MitobanPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV)USP Type I Clear Glass Vial x 5 mL w/ white coloured flip-off Seal Box of 1's | RxVAT-exempt | Adley FormulationsIndia | ASA LIFE PHILIPPINES LIMITED INCTrader: Atlanta Biological Pvt. Ltd. | DRP-5336 | Jun 9, 2028 | |
Mitoban-100Paclitaxel | 6 mg/mL (100 mg /16.7 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal orange color x 16.7 mL (net content) Box of 1's | RxVAT-exempt | ADMAC LifesciencesIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-12327-01 | Jul 15, 2027 | |
Mitoban-260Paclitaxel | 6 mg/mL (260 mg/43.4 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with bromobutyl rubber plug and sealed with flip off seal white color x 43.4 mL (net content) (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-11715-01 | Apr 21, 2027 | |
Mitoban-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal red color x 5 mL (net content). (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-11716-03 | Apr 21, 2027 | |
Nab-PaclinatPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion (Protein-bound particles)50-mL capacity USP Type I Clear and colorless glass vial with grey bromobutyl rubber stopper with aluminum seal and colorless flip-off cap (Box of 1’s) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Natco Lifesciences Philippines Inc.Importer: Ambica International Corporation | DRP-15244-01 | May 31, 2029 | |
NanoxelPaclitaxel | 20mg/mL Solution for Nanoparticle Injection for Infusion (IV)USP Type I clear colorless moulded glass vials x 15mL fill volume in 20mL, with 1 syringe with 20G 2-inch needle Box of 2's; USP Type I clear colorless moulded glass vials x 5mL fill volume in 5mL, with 1 syringe with 20G 2-inch needle Box of 2's; USP Type I clear colorless moulded glass vials x 1.5mL fill volume in 5mL, with 1 syringe with 20G 2-inch needle Box of 2's | RxVAT-exempt | Fresenius Kabi Oncology LimitedIndia | Fresenius Kabi Philippines, Inc. | DR-XY42006 | May 6, 2031 | |
Napro-TaxPaclitaxel | 6 mg/mL Solution for I.V InfusionUSP Type I Amber Glass Vial x 5 mL, 16.67 mL and 43.34 mL (Box of 1's) | RxVAT-exempt | Naprod Lifesciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2736 | Feb 25, 2032 | |
NesataxelPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion (protein-bound particles)Type I clear glass vial x 50 mL with rubber stopper and flip-off seal (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17971 | Apr 16, 2031 | |
NonePaclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal red color x 5 mL (net content) (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-11716-01 | Apr 21, 2027 | |
NonePaclitaxel | 6 mg/mL Concentrate Solution for I.V. Infusion5 mL, 16.7 mL, 25 mL and 50 mL USP Type I Clear Colorless Vial with Butyl Rubber Stopper (Box of 1's) | RxVAT-exempt | FAREVA UNTERACH GMBHAustria | Sandoz Philippines Corporation | DRP-11497 | Apr 5, 2028 | |
NonePaclitaxel | 6 mg/mL Solution for Injection (IV Infusion)USP Type I Clear Glass Vial x 5 mL (Box of 10's); USP Type I Clear Glass Vial x 16.7 mL (Box of 5's); USP Type I Clear Glass Vial x 50 mL (Box of 4's); USP Type I Clear Glass Vial x 5 mL, 16.7 mL, 25 mL and 50 mL (Box of 1's) | RxVAT-exempt | Biolyse Pharma CorporationCanada | Importer: Belcynor Pharmaceuticals Inc. | DRP-8812 | Dec 15, 2026 | |
Pacalitex NABPaclitaxel | 100 mg Lyophilized Powder for Suspension (IV Infusion)50 mL-capacity Type I glass vial, bromobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1’s) | RxVAT-exempt | Kexing Biopharm Co. Ltd.China | Delex Pharma International, Inc. | DRP-18589 | Aug 4, 2031 | |
PacitaxilPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL USP Type I Amber Glass Vial (Net content 16.7 mL) Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4751-04 | Sep 26, 2028 | |
PacitaxilPaclitaxel | 6 mg/mL (260 mg/43.4 mL) Solution for IV Infusion43.4 mL (net content) in 50 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4752-03 | Sep 26, 2028 | |
PacitaxilPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV Infusion)5 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4750-04 | Sep 26, 2028 | |
Pacitel-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL USP Type I Amber Glass Vial (Net content 16.7 mL) Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | IUS Pharmaceutical Products Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4751 | Sep 26, 2028 | |
Pacitel-260Paclitaxel | 6 mg/mL (260 mg/43.4 mL) Solution for IV Infusion43.4 mL (net content) in 50 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4752 | Sep 26, 2028 | |
Pacitel-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV Infusion)5 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | IUS Pharmaceutical Products Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4750 | Sep 26, 2028 | |
Pacli-One 100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL USP Type I Amber Glass Vial (Net content 16.7 mL) Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | OneGen PharmaImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4751-02 | Sep 26, 2028 | |
Pacli-One 30Paclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (I.V. Infusion)5 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | OneGen PharmaImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4750-02 | Sep 26, 2028 | |
PacliAllPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion50 mL USP Type I clear glass vial with bromobutyl rubber stopper, aluminum seal, and brown flip-off cap (Box of 1's) | RxVAT-exempt | Panacea Biotec Pharma Ltd.India | Biocare Lifesciences, Inc. | DRP-18016 | Dec 5, 2030 | |
PaclibPaclitaxel | 6 mg/mL (260 mg/43.4 mL) Solution for IV Infusion43.4 mL Net content in 50 mL USP Type I Amber Glass Vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | UNILAB, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4752-02 | Sep 26, 2028 | |
PaclibPaclitaxel | 6 mg/mL Concetrate Solution (IV)5 mL & 16.67 mL Type I Clear Colorless Glass Vial with secondary box | RxVAT-exempt | Laboratorios Richmond S.A.C.I.F.Republica Argentina | UNILAB, Inc. | DR-XY40175 | Oct 14, 2031 | |
PaclibaxPaclitaxel | 6 mg/mL (30mg/5mL and 150mg/25mL) Concentrate Solution for Injection (IV Infusion)10 mL Type I Clear Colorless Borosilicate Glass Vial Sealed with Chlorobutyl Rubber Stopper and Blue Flip-Off Seal Cap x 5 mL (Net Content) (Box of 1's); 50 mL Type I Clear Colorless Borosilicate Glass Vial Sealed with Chlorobutyl Rubber Stopper and Yellow Flip-Off Seal Cap x 25 mL (Net content) (Box of 1's) (Box of 1's) | RxVAT-exempt | Sobhan Oncology Pharmaceutical CompanyIran | Raquel Abbas Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-11551-01 | Mar 29, 2027 | |
PaclicanPaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection5 mL in 10 mL Capacity USP Type I Clear Glass Vial Box of 1's | RxVAT-exempt | Zee Laboratories LimitedIndia | Eon Pharmatek, Inc | DR-XY42570 | Sep 6, 2028 | |
PaclidexPaclitaxel | 6 mg/mL (30 mg/5 mL; 100 mg/16.67 mL; 150 mg/25 mL; and 300 mg/50 mL) Concentrated Solution for Injection (I.V. Infusion)USP Type I Clear and Colorless Glass Vial x 5 mL, 16.67 mL, 25 mL and 50 mL (net content) with Grey Bromobutyl Elastomeric Stopper (Teflon-treated) and Aluminum Seal with Plastic Flip-off Cap (Box of 1's) | RxVAT-exempt | Laboratorio Varifarma S.A.Argentina | Detoxicare Philippines, Inc. | DRP-11648 | Apr 6, 2027 | |
PacligetPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for IV InfusionUSP Type I Clear Glass Vial with Grey Butyl Rubber Plug and Aluminum Black Flip-off Seal (Box ox of 1's) | RxVAT-exempt | Venus Remedies Limited.India | 2MG Incorporated | DRP-14666 | Nov 21, 2028 | |
PacliGetPaclitaxel | 6mg/mL Solution for Injection (IV Infusion)50 mL-Type I Clear Glass Vial Sealed with Gray Butyl Rubber Stopper and Black Aluminum Flip-Off Cap x 43.4 mL (net content) (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | 2MG Incorporated | DRP-16492 | Mar 28, 2030 | |
PacliGet-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (I.V. Infusion) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-17606 | Feb 19, 2031 | |
PacliGet-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Infusion (I.V.)USP Type I moulded clear glass vial x 5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | 2MG Incorporated | DRP-18392 | Jun 30, 2031 | |
PacliGet-300Paclitaxel | 6 mg/mL (300 mg/50 mL) Solution for Injection (I.V. Infusion) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-17607 | Feb 19, 2031 | |
PacliGet-300Paclitaxel | 6 mg/mL (300 mg/50 mL) Solution for IV InfusionUSP Type I clear glass vial with grey butyl rubber stopper with black aluminum-polypropylene flip-off seal x 50 mL (Box of 1's) | RxVAT-exempt | Venus Remedies Limited.India | 2MG Incorporated | DRP-15955 | Oct 4, 2029 | |
PaclihopePaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for (I.V.) InfusionType I Amber Glass Vial x 5 mL and 50 mL (Box of 1's) | RxVAT-exempt | Glenmark Generics S.A.Argentine Republic | Glenmark Philippines, Inc. | DRP-9410 | Jun 6, 2028 | |
Paclimed-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution for Infusion (IV)20 mL Type I clear tubular glass vial with 20 mm rubber stopper and 20 mm black aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8583-03 | Dec 18, 2029 | |
Paclimed-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution for Infusion (IV)5 mL Type I Clear Moulded Glass Vial with 20 mm Rubber Stopper and 20 mm Black Aluminum Flip-Off Seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8582-03 | Dec 18, 2029 | |
PaclinabPaclitaxel | 100mg Lyophilized Powder for Suspension for IV InfusionType I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Pink PP Flip- Off (Box of 1's) | RxVAT-exempt | Nano Daru Pajuhan Pardis Pharmaceutical CompanyIran | S.M.H.P. Marketing & ConsultancyTrader: Zima | DRP-16744 | Jul 4, 2030 | |
PaclinanoPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion (Protein-bound particles)50-mL capacity USP Type I Clear and colorless glass vial with grey bromobutyl rubber stopper with aluminum seal and colorless flip-off cap (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-15243 | May 31, 2029 | |
Paclinish 30Paclitaxel | 6mg/mL (30mg/5mL) Solution for Injection for I.V. InfusionUSP Type I amber colour moulded glass vial with bromo butyl rubber plug and red colour flip off seal x 5 mL (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-17885 | Mar 30, 2031 | |
Paclinish-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Intravenous Infusion20 mL USP Type I Clear Glass Vial x 16.7 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-8802 | Oct 3, 2028 | |
Paclinish-260Paclitaxel | 6 mg/mL (260 mg/43.4mL) Solution for Intravenous InfusionUSP Type I Clear Glass Vial x 50 mL (Net content 43.4 mL) Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-8801 | Oct 3, 2028 | |
PaclisanzPaclitaxel | 6 mg/mL Solution for IV InfusionUSP Type I Clear and Colorless Glass Vial x 5 mL, 16.7 mL and 43.4 mL (Net Content) Box of 1's | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Unicare Healthsciences Private Limited | DRP-9326 | Apr 22, 2028 | |
PacliSaya-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for IV InfusionUSP Type I Clear Glass Vial with Grey Butyl Rubber Plug and Aluminum Black Flip-off Seal (Box of 1’s) | RxVAT-exempt | Venus Remedies, LimitedIndia | Getmeds Philippines Inc.Importer: 2MG Incorporated | DRP-14666-01 | Nov 21, 2028 | |
PacliSaya-260Paclitaxel | 6 mg/mL Solution for Injection (IV Infusion)50 mL-Type I Clear Glass Vial Sealed with Gray Butyl Rubber Stopper and Black Aluminum Flip-Off Cap x 43.4 mL (net content) (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Getmeds Philippines, Inc.Importer: 2MG Incorporated | DRP-16492-01 | Mar 28, 2030 | |
Paclisaya-300Paclitaxel | 6 mg/mL (300 mg/50 mL) Solution for IV InfusionUSP Type I clear glass vial with grey butyl rubber stopper with black aluminum-polypropylene flip-off seal x 50 mL (Box of 1’s) | RxVAT-exempt | Venus Remedies LimitedIndia | Getmeds Philippines, Inc.Importer: 2MG Incorporated | DRP-15955-01 | Oct 4, 2029 | |
Paclisun 300Paclitaxel | 300 mg/2.73 mL Concentrate Solution for IV Infusion (albumin-free Concentrate for Nanodispersion)5mL-capacity USP Type I colourless tubular glass vial with grey bromobutyl rubber stopper and golden red aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Sun Pharmaceutical Industries Ltd., IndiaIndia | Sun Pharma Philippines, Inc. | DR-XY46655 | Dec 9, 2026 | |
PacliteroPaclitaxel | 6mg/mL Solution for I.V. Infusion5mL USP Type 1 clear and colorless glass vial (Box of 1 vial); 16.7 mL USP Type 1 clear and colorless glass vial (Box of 1 vial); 50 mL USP Type 1 clear and colorless glass vial (Box of 1 vial) | RxVAT-exempt | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DR-XY46101 | Oct 18, 2029 | |
PaclitexPaclitaxel | 100 mg/17 mL Concentrate for Solution for I.V. Infusion17 mL capacity USP Type I Glass Vial (Box of 1's) | RxVAT-exempt | Laboratorio Kemex S.A.Argentine Republic | Delex Pharma International, Inc. | DR-XY41520 | Dec 27, 2031 | |
PaclitexPaclitaxel | 6 mg/mL (30mg/5mL) Solution for InjectionUSP Type I Clear Glass Vial x 5 mL and 50 mL Box of 1's | RxVAT-exempt | LABORATORIO KEMEX S.A.Argentine Republic | DELEX PHARMA INTERNATIONAL, INC. | DR-XY41019 | Jul 9, 2027 | |
PacliusPaclitaxel | 6 mg/mL (260 mg/43.4mL) Solution for Intravenous InfusionUSP Type I Clear Glass Vial x 50 mL (Net content 43.4 mL ) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | IUS BIO Pharmaceutical Care Enterprises Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8801-03 | Oct 3, 2028 | |
Paclius-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Intravenous Infusion20 mL USP Type I Clear Glass Vial x 16.7 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | IUS Bio Pharmaceutical Care Enterprises Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8802-04 | Oct 3, 2028 | |
PacliwelPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution For IV InfusionUSP Type I glass vial x 20 mL, with rubber stopper, aluminum seal, and Flip-off Cap (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-19052 | Oct 21, 2031 | |
PacliwelPaclitaxel | 6 mg/mL (260 mg/43.4 mL) Concentrate Solution For IV InfusionUSP Type I Glass Vial x 43.4 mL, with rubber stopper, aluminum seal and flip-off cap (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-19053 | Oct 21, 2031 | |
PacliwelPaclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution For IV InfusionUSP Type I Glass Vial x 5 mL, with rubber stopper, aluminum seal, and flip-off cap (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-19051 | Oct 21, 2031 | |
PaclizelPaclitaxel | 100 mg/16.7 mL Solution for Infusion (I.V.)USP Type I clear glass vial x 20 mL (Box of 1's) | RxVAT-exempt | Haikou Pharmaceutical Factory Co., Ltd.China | Global Pharmatrade | DRP-15014 | Dec 26, 2027 | |
PaclizelPaclitaxel | 100mg/16.7mL Solution for Infusion (I.V.)USP Type I Clear Glass Vial x 20mL (Box of 1's) | RxVAT-exempt | Haikou Pharmaceutical Factory Co., Ltd.China | Global Pharmatrade | DR-XY41526 | Dec 26, 2027 | |
PaclizelPaclitaxel | 6 mg/mL Solution for Infusion (IV)USP Type I Clear Glass Vial x 5 mL, 25 mL and 50 mL (Box of 1's) | RxVAT-exempt | Haikou Pharmaceutical Factory Co., Ltd.China | Global Pharmatrade | DRP-15015 | Jul 30, 2030 | |
PaclizelPaclitaxel | 6mg/mL Solution for Infusion (I.V.)USP Type I Clear Glass Vial x 5mL (Box of 1's) | RxVAT-exempt | Haikou Pharmaceutical Factory Co., Ltd.China | Global Pharmatrade | DR-XY41534 | Dec 27, 2027 | |
PanataxelPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate for Solution for Injection (IV)USP Type 1 Clear Glass Vial x 16.7 mL with blue flip-off seal (Box of 1’s) | RxVAT-exempt | Laboratorios IMA S.A.I.C.Argentine Republic | Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A. | DR-XY45195 | Mar 28, 2031 | |
PanataxelPaclitaxel | 6 mg/mL (150 mg/25 mL) Concentrate for Solution for Injection (IV)USP Type 1 Clear Glass Vial x 25 mL with white flip-off seal (Box of 1’s) | RxVAT-exempt | Laboratorios IMA S.A.I.C.Argentine Republic | Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A. | DR-XY45196 | Mar 28, 2031 | |
PanataxelPaclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate for Solution for Injection (IV)USP Type 1 Clear Glass Vial x 5 mL with gray flip-off seal (Box of 1’s) | RxVAT-exempt | Laboratorios IMA S.A.I.C.Argentine Republic | Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A. | DR-XY45194 | Mar 28, 2031 | |
PaxelPaclitaxel | 100 mg/16.7 mL Solution for Injection (IV)Clear Amber Type I Glass Vial x 16.7 mL (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Oncolife Corporation | DR-XY35257 | Dec 23, 2036 | |
PaxelPaclitaxel | 30 mg/5 mL Solution for Injection (IV)Type I clear amber glass vial x 5 mL (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Oncolife Corporation | DRP-7263 | Oct 24, 2028 | |
PaxHealth 100Paclitaxel | 6 mg/mL (100mg/16.7 mL) Solution for Intravenous Infusion20 mL USP Type I Clear Glass Vial x 16.7 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8802-02 | Oct 3, 2028 | |
PaxHealth 260Paclitaxel | 6 mg / mL (260 mg / 43.4 mL) Solution for Intravenous InfusionUSP Type I Clear Glass Vial x 50 mL (Net content 43.4 mL) (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8801-02 | Oct 3, 2028 | |
PaxikemPaclitaxel | 6 mg/mL (100 mg/ 16. 7 mL) Solution for Injection (IV Infusion)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 16.7 mL (Net Content) (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited-Rupganj PlantBangladesh | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-12602-01 | Sep 13, 2027 | |
PaxolPaclitaxel | 6 mg/mL (260 mg/ 43.4 mL) Concentrate Solution for Injection (IV Infusion)50 mL Type I Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 43.4 mL (Net content) (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Healol Pharma Corporation | DRP-11495 | Mar 17, 2027 | |
PaxolPaclitaxel | 6 mg/mL (300 mg/50 mL) Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 50 mL (Box of l’s) | RxVAT-exempt | Venus Remedies, LimitedIndia | Healol Pharma Corporation | DRP-11494 | Mar 17, 2027 | |
PAXUSPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution for IV Infusion20 mL Type I Clear glass vial with grey bromo butyl rubber stopper, aluminum seal, and flip-off cap x 16.7 mL (net content) (Box of 1’s) | RxVAT-exempt | Pt. Global Onkolab FarmaIndonesia | Globo Asiatico Enterprises, Inc.Trader: Kalbe International Enterprises, Inc. | DR-XY49146 | Jul 31, 2031 | |
Paxus 30Paclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Injection (IV Infusion)10 mL Type I Clear Vial Sealed with Gray Bromobutyl Rubber Stopper and White Silver Aluminum Flip-Off Seal Cap x 5 mL (Net content) (Box of l's) | RxVAT-exempt | PT Global Onkolab FarmaIndonesia | Globo Asiatico Enterprises, Inc. | DR-XY47823 | Mar 17, 2027 | |
Paxus PMPaclitaxel | 100 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial with Gray Butyl Rubber Stopper and Aluminum Seal with Green-Colored Plastic Flip-Off Cap (Box of 1 Vial) | RxVAT-exempt | Samyang Holdings CorporationRepublic of Korea | Globo Asiatico Ent. Inc.Trader: Kalbe International Pte. Ltd. | DR-XY35833 | Nov 10, 2029 | |
Paxus PMPaclitaxel | 30 mg Lyophilized Powder for Injection (I.V.)USP Type I clear and colorless glass vial with gray butyl rubber stopper and aluminum seal with orange colored plastic flip-off cap (Box of 1 vial) | RxVAT-exempt | Samyang Holdings Corp.Republic of Korea | Globo Asiatico Enterprises, Inc.Trader: Kalbe International Pte. Ltd. | DR-XY35832 | Nov 10, 2029 | |
Paxwind 100Paclitaxel | 6mg/mL (100mg/16.7mL) Solution for Intravenous Infusion20 mL USP Type I Clear Glass Vial x 16.7 mL (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8802-01 | Oct 3, 2028 | |
Paxwind 260Paclitaxel | 6 mg/mL (260 mg/43.4 mL) Solution for Intavenous Infusion50 mL USP Type I Clear Glass Vial x 43.4 mL (Box of 1's) | RxVAT-exempt | — | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8801-01 | Oct 3, 2028 | |
SaphxelPaclitaxel | 6 mg/mL Solution for I.V. InfusionUSP Type I clear glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) 5 mL (30 mg/5 mL net content); 20 mL (100 mg/16.7 mL net content); 50 mL (260 mg/43.4 mL net content); 50 mL (300 mg/50.0 mL net content) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10592 | Oct 26, 2031 | |
Taxaica-100Paclitaxel | 6 mg/mL (100 mg/ 16.7 mL) Concentrate Solution for IV Infusion50 mL USP Type I Amber Moulded Glass Vial with 20 mm Bromobutyl Rubber Plug and Sealed with 20 mm White Flip-off Seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International Corporation | DRP-12465 | Aug 15, 2027 | |
Taxaica-260Paclitaxel | 6 mg/mL (260 mg/43.4 mL) Concentrate Solution for IV Infusion50 mL USP Type I Amber Moulded Glass Vial with 20 mm Bromobutyl Rubber Plug and Sealed with 20 mm White Flip-off Seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International Corporation | DRP-12464 | Aug 15, 2027 | |
Taxaica-30Paclitaxel | 6mg/mL (30mg/5mL) Concentrate For Solution For InfusionUSP Type I Amber glass vial with grey bromobutyl rubber stopper and red flip-off seal x 5 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International Corporation | DRP-14053 | Jun 8, 2028 | |
Taxaica-300Paclitaxel | 6 mg/mL (300 mg/50 mL) Concentrate Solution for Injection for I.V. InfusionUSP Type I amber color molded glass vial with bromobutyl rubber plug and sealed with pink color flip off seal x 50 mL (net content). Box of l’s. | RxVAT-exempt | ADMAC LifesciencesIndia | Ambica International Corporation | DRP-12444 | Aug 9, 2027 | |
TaxcelPaclitaxel | 6 mg / mL (260 mg/43.4 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with bromobutyl rubber plug and sealed with flip off seal white color x 43.4 mL (net content) (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Amediqo Phils., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-11715-02 | Apr 21, 2027 | |
TaxcelPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution for I.V. InjectionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal orange color x 16.7 mL (net content) (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Amediqo Phils., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-12327-02 | Jul 15, 2027 | |
TaxcelPaclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal red color x 5 mL (net content) (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Amediqo Phils., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-11716-02 | Apr 21, 2027 | |
TaxelbenePaclitaxel | 6 mg/mL ( 100 mg/ 16. 7 mL) Solution for Intravenous InfusionUSP Type l clear and colorless glass vial with red flip-off seal x 16.7 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix Inc.Importer: I.E. Medica Inc. | DRP-2241-01 | Feb 25, 2031 | |
TaxelbenePaclitaxel | 6 mg/mL (260 mg/43.3 mL) Solution for Intravenous InfusionUSP Type I clear and colorless glass vial with red flip-off seal x 43.3 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-2240-01 | Jun 13, 2031 | |
TaxelbenePaclitaxel | 6 mg/mL (30 mg/5 mL) Solution for Intravenous InfusionUSP Type l clear and colorless glass vial with red flip off seal x 5 mL & 25 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix Inc.Importer: I.E. Medica Inc. | DRP-2239-01 | Feb 25, 2031 | |
TaxeldixPaclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 16.7 mL (Net Content) (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited-Rupganj PlantBangladesh | Zeldix Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-12602-02 | Sep 13, 2027 | |
TaxinanoPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion (Protein-bound particles)50-mL capacity USP Type I Clear and colorless glass vial with grey bromobutyl rubber stopper with aluminum seal and colorless flip-off cap (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-15244 | May 31, 2029 | |
Taxitas-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate Solution for I.V. InfusionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal orange color x 16.7 mL (net content). Box of l’s. | RxVAT-exempt | ADMAC LifesciencesIndia | Suhitas Pharmaceuticals Inc. | DRP-12327 | Jul 15, 2027 | |
Taxitas-260Paclitaxel | 6 mg/mL (260 mg/43.4 mL) Concentrate for Solution for InfusionUSP Type I amber color molded glass vial with bromobutyl rubber plug and sealed with flip off seal white color x 43.4 mL (net content). Box of 1's. | RxVAT-exempt | ADMAC LifesciencesIndia | Suhitas Pharmaceuticals Inc. | DRP-11715 | Apr 21, 2027 | |
Taxitas-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate for Solution for InfusionUSP Type I amber color molded glass vial with grey bromobutyl rubber plug and sealed with flip off seal red color x 5 mL (net content). Box of 1's. | RxVAT-exempt | ADMAC LifesciencesIndia | Suhitas Pharmaceuticals Inc. | DRP-11716 | Apr 21, 2027 | |
Unipacli-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Solution for IV Infusion16.7 mL (net content in 20 mL USP Type I Amber Moulded Glass Vial with 20 mm bromobutyl rubber plug and sealed with 20 mm orange color flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | AGE Pharmaceutical Trading and ConsultancyImporter: Unicare Health sciences Pvt. Ltd. | DRP-12765 | Oct 6, 2027 | |
Unipacli-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Solution for IV Infusion5 mL USP Type I Amber Moulded Glass Vial with 20 mm bromobutyl rubber plug and sealed with 20 mm red color flip-off seal (Box of l's) | RxVAT-exempt | Admac LifesciencesIndia | AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-12766 | Oct 6, 2027 | |
UnitaxelPaclitaxel | 6 mg/mL Solution for I.V. InfusionUSP Type I amber coloured glass vial x 30 mg/5 mL (Box of 1's); USP Type I amber coloured glass vial x 100 mg/16.67 mL (Box of 1's); USP Type I amber coloured glass vial x 150 mg/25 mL (Box of 1's); USP Type I amber coloured glass vial x 300 mg/50 mL (Box of 1's) | RxVAT-exempt | KOREA UNITED PHARM. INC.Republic of Korea | QUALIMED PHARMA INC. | DR-XY28408 | Oct 4, 2028 | |
Vexel-100Paclitaxel | 6 mg/mL (100 mg/16.7 mL) Concentrate for Solution for IV Infusion20 mL- capacity USP Type I Clear and Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | Importer: VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY43608 | Aug 6, 2029 | |
Vexel-30Paclitaxel | 6 mg/mL (30 mg/5 mL) Concentrate for Solution for IV Infusion5 mL-capacity USP Type I Clear and Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY43607 | Aug 6, 2029 | |
Vexel-300Paclitaxel | 6 mg/mL (300 mg/50 mL) Concentrate for Solution for IV InfusionClear moulded USP Type I Glass vial with grey bromo butyl rubber stopper and orange aluminum flip-off seal x 50 mL (Box of 1’s) | RxVAT-exempt | ADMAC LIFESCIENCESIndia | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY43923 | Dec 1, 2029 | |
WelnanoPaclitaxel | 100 mg Lyophilized Powder for Suspension for IV Infusion (Protein-bound particles)50-mL capacity USP Type I Clear and colorless glass vial with grey bromobutyl rubber stopper with aluminum seal and colorless flip-off cap (Box of 1's) | RxVAT-exempt | Getwell Pharmaceuticals.India | Ambica International Corporation.Importer: Ambica International Corporation | DRP-15245 | May 31, 2029 | |
XeltixPaclitaxel | 6 mg/mL (100mg/16.67 mL) Solution for Intravenous InfusionUSP Type I clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 16.67 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-16589 | May 30, 2030 | |
XeltixPaclitaxel | 6 mg/mL (150 mg/25mL) Solution For Intravenous InfusionUSP Type I Clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 25 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-18043 | Apr 30, 2031 | |
XeltixPaclitaxel | 6 mg/mL (260 mg/ 43.4 mL) Solution for Intravenous InfusionUSP Type I Clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 43.4 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-18041 | Apr 30, 2031 | |
XeltixPaclitaxel | 6 mg/mL (30 mg/5mL) Solution For Intravenous InfusionUSP Type I Clear Glass Vial x 5 mL | RxVAT-exempt | TherDose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-18045 | Apr 30, 2031 | |
(no brand name)Paclitaxel | 6 mg/ mL (100 mg/16.7 mL) Solution for Injection (IV Infusion)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip Off Seal Cap x 16.7 mL (Net content) (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited - Rupganj PlantBangladesh | Firmlink Pharma Phils., Co. | DR-XY48313 | Aug 25, 2027 | |
(no brand name)Paclitaxel | 6 mg/mL (100mg/16.67 mL) Solution for Intravenous InfusionUSP Type I clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 16.67 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-16590 | May 30, 2030 | |
(no brand name)Paclitaxel | 6 mg/mL (150 mg/25mL) Solution For Intravenous InfusionUSP Type I Clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 25 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-18044 | Apr 30, 2031 | |
(no brand name)Paclitaxel | 6 mg/mL (260 mg/ 43.4 mL) Solution For Intravenous InfusionUSP Type I Clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 43.4 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt.Ltd.India | MedEthix, Inc.Trader: TherDose Pharma Pvt. Ltd. | DRP-18042 | Apr 30, 2031 | |
(no brand name)Paclitaxel | 6 mg/mL (30 mg/5mL) Solution For Intravenous InfusionUSP Type I Clear glass vial with grey bromobutyl rubber stopper and light pink-colored aluminum flip- off seal x 5 mL (Box of 1's) | RxVAT-exempt | TherDose Pharma Pvt. Ltd.Philippines | MedEthix, Inc. | DRP-18046 | Apr 30, 2031 | |
(no brand name)Paclitaxel | 6 mg/mL (300 mg/50 mL) Concentrate for Solution for IV InfusionUSP Type I Glass Vial with Grey Bromo Butyl Rubber Stopper and Black colored Aluminum-Plastic Flip-Off Seal x 50 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | VE Pharma Inc. | DR-XY48376 | Sep 28, 2027 | |
(no brand name)Paclitaxel | 6 mg/mL (300 mg/50 mL) Solution for Injection (IV Infusion)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Pink Aluminum Flip-Off Seal Cap x 50 mL (Box of 1's) | RxVAT-exempt | Eskayef Pharmaceuticals Limited - Rupganj PlantBangladesh | Firmlink Pharma Phils., Co. | DR-XY48314 | Aug 25, 2027 | |
6mg/mL (100mg / 16.7mL) Solution for IV InfusionClear Glass Vial (Type I) x 20mL with Aluminum Flip off Seal Cap and Bromo Butyl Fluro Coated Rubber Stopper (Box of l’s) | Rx | Venus Remedies, LimitedIndia | VE Pharma Inc. | DR-XY47925 | Apr 13, 2027 | ||
(no brand name)Paclitaxel | 6mg/mL (30mg/5mL) Concentrate Solution for IV InfusionUSP Type I clear glass vial (with bromobutyl rubber stopper and aluminum flip-off seal) x 5 mL (box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY48781 | Jun 23, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS For injectable suspension, for intravenous use: white to yellow, sterile lyophilized powder containing 100 mg of paclitaxel formulated as albumin-bound particles in single-dose vial for reconstitution. For injectable suspension: white to yellow, sterile, lyophilized powder containing 100 mg of paclitaxel formulated as albumin-bound particles in single-dose vial for reconstitution. (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Sensory neuropathy occurs frequently and may require dose reduction or treatment interruption. (5.2)
- • Sepsis occurred in patients with or without neutropenia who received ABRAXANE in combination with gemcitabine; interrupt ABRAXANE and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1500 cells/mm 3, then resume treatment at reduced dose levels. (5.3)
- • Pneumonitis occurred with the use of ABRAXANE in combination with gemcitabine; permanently discontinue treatment with ABRAXANE and gemcitabine. (5.4)
- • Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. (4, 5.5) • Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. (2.5, 5.6)
- • ABRAXANE contains albumin derived from human blood, which has a theoretical risk of viral transmission. (5.7)
- • ABRAXANE can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (5.8, 8.1, 8.3)
5.1 Severe Myelosuppression
5.1 Severe Myelosuppression Severe myelosuppression (primarily neutropenia) is dose-dependent and a dose-limiting toxicity of ABRAXANE. In clinical studies, Grade 3-4 neutropenia occurred in 34% of patients with metastatic breast cancer (MBC), 47% of patients with non-small cell lung cancer (NSCLC), and 38% of patients with pancreatic cancer.
Monitor for severe neutropenia and thrombocytopenia by performing complete blood cell counts frequently, including prior to dosing on Day 1 (for MBC) and Days 1, 8, and 15 (for NSCLC and for pancreatic cancer). Do not administer ABRAXANE to patients with baseline absolute neutrophil counts (ANC) of less than 1,500 cells/mm3 [see Contraindications (4)].
In the case of severe neutropenia (<500 cells/mm 3 for seven days or more) during a course of ABRAXANE therapy, reduce the dose of ABRAXANE in subsequent courses in patients with either MBC or NSCLC. In patients with MBC, resume treatment with every-3-week cycles of ABRAXANE after ANC recovers to a level >1,500 cells/mm 3 and platelets recover to a level >100,000 cells/mm 3.
In patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly ABRAXANE and every-3-week carboplatin after ANC recovers to at least 1500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an ANC of at least 500 cells/mm 3 and platelet count of at least 50,000 cells/mm 3 on Days 8 or 15 of the cycle [see Dosage and Administration (2.6)]. In patients with adenocarcinoma of the pancreas, withhold ABRAXANE and gemcitabine if the ANC is less than 500 cells/mm 3 or platelets are less than 50,000 cells/mm 3 and delay initiation of the next cycle if the ANC is less than 1500 cells/mm 3 or platelet count is less than 100,000 cells/mm 3 on Day 1 of the cycle.
Resume treatment with appropriate dose reduction if recommended [see Dosage and Administration (2.6)].
5.2 Severe Neuropathy
5.2 Severe Neuropathy Sensory neuropathy is dose- and schedule-dependent [see Adverse Reactions (6.1)]. If ≥ Grade 3 sensory neuropathy develops, withhold ABRAXANE treatment until resolution to Grade 1 or 2 for metastatic breast cancer or until resolution to ≤ Grade 1 for NSCLC and pancreatic cancer followed by a dose reduction for all subsequent courses of ABRAXANE [see Dosage and Administration (2.6)].
5.3 Sepsis
5.3 Sepsis Sepsis occurred in 5% of patients with or without neutropenia who received ABRAXANE in combination with gemcitabine. Biliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis. If a patient becomes febrile (regardless of ANC) initiate treatment with broad spectrum antibiotics.
For febrile neutropenia, interrupt ABRAXANE and gemcitabine until fever resolves and ANC ≥ 1500, then resume treatment at reduced dose levels [see Dosage and Administration (2.6)].
5.4 Pneumonitis
5.4 Pneumonitis Pneumonitis, including some cases that were fatal, occurred in 4% of patients receiving ABRAXANE in combination with gemcitabine. Monitor patients for signs and symptoms of pneumonitis and interrupt ABRAXANE and gemcitabine during evaluation of suspected pneumonitis. After ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with ABRAXANE and gemcitabine.
5.5 Severe Hypersensitivity
5.5 Severe Hypersensitivity Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported. Do not rechallenge patients who experience a severe hypersensitivity reaction to ABRAXANE with this drug [see Contraindications (4)]. Cross-hypersensitivity between ABRAXANE and other taxane products has been reported and may include severe reactions such as anaphylaxis.
Closely monitor patients with a previous history of hypersensitivity to other taxanes during initiation of ABRAXANE therapy.
5.6 Use in Patients with Hepatic Impairment
5.6 Use in Patients with Hepatic Impairment The exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment. Closely monitor patients with hepatic impairment for severe myelosuppression. ABRAXANE is not recommended in patients who have total bilirubin >5 x ULN or AST >10 x ULN. In addition, ABRAXANE is not recommended in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment (total bilirubin >1.5 x ULN and AST ≤10 x ULN).
Reduce the starting dose for patients with moderate or severe hepatic impairment [see Dosage and Administration (2.5), Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
5.7 Albumin (Human)
5.7 Albumin (Human) ABRAXANE contains albumin (human), a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote.
No cases of transmission of viral diseases or CJD have ever been identified for albumin.
5.8 Embryo-Fetal Toxicity
5.8 Embryo-Fetal Toxicity Based on mechanism of action and findings in animals, ABRAXANE can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to rats during pregnancy at doses lower than the maximum recommended human dose, based on body surface area, caused embryo-fetal toxicities, including intrauterine mortality, increased resorptions, reduced numbers of live fetuses, and malformations.
Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception and avoid becoming pregnant during treatment with ABRAXANE and for at least six months after the last dose of ABRAXANE [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)].
Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with ABRAXANE and for at least three months after the last dose of ABRAXANE [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS The metabolism of paclitaxel is catalyzed by CYP2C8 and CYP3A4. Caution should be exercised when administering ABRAXANE concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4. Use caution when concomitantly administering ABRAXANE with inhibitors or inducers of either CYP2C8 or CYP3A4. (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism In vitro studies with human liver microsomes and tissue slices showed that paclitaxel in ABRAXANE was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'- p -hydroxypaclitaxel and 6α, 3'- p -dihydroxypaclitaxel, by CYP3A4.
Testosterone, 17α-ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of CYP2C8, also inhibited the formation of 6α-hydroxypaclitaxel in vitro .
The pharmacokinetics of paclitaxel may also be altered in vivo as a result of interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 and/or CYP3A4 [see Drug Interactions (7) ] .
7 DRUG INTERACTIONS The metabolism of paclitaxel is catalyzed by CYP2C8 and CYP3A4.
Caution should be exercised when administering ABRAXANE concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4.
Use caution when concomitantly administering ABRAXANE with inhibitors or inducers of either CYP2C8 or CYP3A4.
Adverse reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (≥ 20%) with single-agent use of ABRAXANE in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea [see Adverse Reactions (6.1)].
The most common adverse reactions (≥ 20%) of ABRAXANE in combination with carboplatin for non-small cell lung cancer are anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue [see Adverse Reactions (6.1)]. The most common serious adverse reactions of ABRAXANE in combination with carboplatin for non-small cell lung cancer are anemia (4%) and pneumonia (3%).
The most common adverse reactions resulting in permanent discontinuation of ABRAXANE are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%). The most common adverse reactions resulting in dose reduction of ABRAXANE are neutropenia (24%), thrombocytopenia (13%), and anemia (6%). The most common adverse reactions leading to withholding or delay in ABRAXANE dosing are neutropenia (41%), …
6.1 Clinical Trials Experience Metastatic Breast Cancer
6.1 Clinical Trials Experience Metastatic Breast Cancer Table 6 shows the frequency of important adverse reactions in the randomized comparative trial for the patients who received either single-agent ABRAXANE or paclitaxel injection for the treatment of metastatic breast cancer. Table 6: Adverse Reactions in the Randomized Metastatic Breast Cancer Study on an Every-3-Weeks Schedule a Paclitaxel injection patients received premedication. b Includes treatment-related events related to hypersensitivity (e.g., flushing, dyspnea, chest pain, hypotension) that began on a day of dosing. c Severe events are defined as at least Grade 3 toxicity.
Percent of Patients ABRAXANE 260 mg/m 2 over 30 min (n=229) Paclitaxel Injection 175 mg/m 2 over 3 h a (n=225) Bone Marrow Neutropenia < 2.0 x 10 9 /L 80 82 < 0.5 x 10 9 /L 9 22 Thrombocytopenia < 100 x 10 9 /L 2 3 < 50 x 10 9 /L <1 <1 Anemia < 11 g/dL 33 25 < 8 g/dL 1 <1 Infections 24 20 Febrile Neutropenia 2 1 Neutropenic Sepsis <1 <1 Bleeding 2 2 Hypersensitivity Reaction b All 4 12 Severe c 0 2 Cardiovascular Vital Sign Changes During Administration Bradycardia <1 <1 Hypotension 5 5 Severe Cardiovascular Events c 3 4 Abnormal ECG All Patients 60 52 Patients with Normal Baseline 35 30 Respiratory Cough 7 6 Dyspnea 12 9 Sensory Neuropathy Any Symptoms 71 56 Severe Symptoms c 10 2 Myalgia / Arthralgia Any Symptoms 44 49 Severe Symptoms c 8 4 Asthenia Any Symptoms 47 39 Severe Symptoms c 8 3 Fluid Retention/Edema Any Symptoms 10 8 Severe Symptoms c 0 <1 Gastrointestinal Nausea Any Symptoms 30 22 Severe Symptoms c 3 <1 Vomiting Any Symptoms 18 10 Severe Symptoms c 4 1 Diarrhea Any Symptoms 27 15 Severe Symptoms c <1 1 Mucositis Any Symptoms 7 6 Severe Symptoms c <1 0 Alopecia 90 94 Hepatic (Patients with Normal Baseline) Bilirubin Elevations 7 7 Alkaline Phosphatase Elevations 36 31 AST (SGOT) Elevations 39 32 Injection Site Reaction <1 1 Other Adverse Reactions Hematologic Disorders Neutropenia was dose dependent and reversible. Among patients with metastatic breast cancer in the randomized trial, neutrophil counts declined below 500 cells/mm 3 (Grade 4) in 9% of the patients treated with a dose of 260 mg/m 2 compared to 22% in patients receiving paclitaxel injection at a dose of 175 mg/m 2.
Pancytopenia has been observed in clinical trials. Infections Infectious episodes were reported in 24% of the patients treated with ABRAXANE. Oral candidiasis, respiratory tract infections and pneumonia were the most frequently reported infectious complications. Hypersensitivity Reactions (HSRs) Grade 1 or 2 HSRs occurred on the day of ABRAXANE administration and consisted of dyspnea (1%) and flushing, hypotension, chest pain, and arrhythmia (all <1%).
The use of ABRAXANE in patients previously exhibiting hypersensitivity to paclitaxel injection or human albumin has not been studied. Cardiovascular Hypotension, during the 30-minute infusion, occurred in 5% of patients. Bradycardia, during the 30-minute infusion, occurred in <1% of patients. These vital sign changes most often caused no symptoms and required neither specific therapy nor treatment discontinuation.
Severe cardiovascular events possibly related to single-agent ABRAXANE occurred in approximately 3% of patients. These events included cardiac ischemia/infarction, chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension. Cases of cerebrovascular attacks (strokes) and transient ischemic attacks have been reported.
Electrocardiogram (ECG) abnormalities were common among patients at baseline. ECG abnormalities on study did not usually result in symptoms, were not dose-limiting, and required no intervention. ECG abnormalities were noted in 60% of patients. Among patients with a normal ECG prior to study entry, 35% of all patients developed an abnormal tracing while on study.
The most frequently reported ECG modifications were non-specific repolarization abnormalities, sinus bradycardia, and sinus tachycardia. Respiratory Dyspnea (12%), cough (7%), and pneumothorax (<1%) were reported after treatment with ABRAXANE. Neurologic The frequency and severity of sensory neuropathy increased with cumulative dose.
Sensory neuropathy was the cause of ABRAXANE discontinuation in 7/229 (3%) patients. Twenty-four patients (10%) treated with ABRAXANE developed Grade 3 peripheral neuropathy; of these patients, 14 had documented improvement after a median of 22 days; 10 patients resumed treatment at a reduced dose of ABRAXANE and 2 discontinued due to peripheral neuropathy.
Of the 10 patients without documented improvement, 4 discontinued the study due to peripheral neuropathy. No Grade 4 sensory neuropathies were reported. Only one incident of motor neuropathy (Grade 2) was observed in either arm of the controlled trial. Vision Disorders Ocular/visual disturbances occurred in 13% of all patients (n=366) treated with ABRAXANE and 1% were severe.
The severe cases (keratitis and blurred vision) were reported in patients who received higher doses than those recommended (300 or 375 mg/m 2). These effects generally have been reversible. Arthralgia/Myalgia The symptoms were usually transient, occurred two or three days after ABRAXANE administration, and resolved within a few days.
Hepatic Grade 3 or 4 elevations in GGT were reported for 14% of patients treated with ABRAXANE and 10% of patients treated with paclitaxel injection in the randomized trial. Renal Overall 11% of patients experienced creatinine elevation, 1% severe. No discontinuations, dose reductions, or dose delays were caused by renal toxicities.
Other Clinical Events Nail changes (changes in pigmentation or discoloration of nail bed) have been reported. Edema occurred in 10% of patients; no patients had severe edema. Dehydration and pyrexia were also reported. Non-Small Cell Lung Cancer Adverse reactions were assessed in 514 ABRAXANE/carboplatin-treated patients and 524 paclitaxel injection/carboplatin-treated patients receiving first-line systemic treatment for locally advanced (stage IIIB) or metastatic (IV) non-small cell lung cancer (NSCLC) in a multicenter, randomized, open-label trial.
ABRAXANE was administered as an intravenous infusion over 30 minutes at a dose of 100 mg/m 2 on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel injection was administered as an intravenous infusion over 3 hours at a dose of 200 mg/m 2, following premedication. In both treatment arms carboplatin at a dose of AUC = 6 mg•min/mL was administered intravenously on Day 1 of each 21-day cycle after completion of ABRAXANE/paclitaxel infusion.
The differences in paclitaxel dose and schedule between the two arms limit direct comparison of dose- and schedule-dependent adverse reactions. Among patients evaluable for adverse reactions, the median age was 60 years, 75% were men, 81% were White, 49% had adenocarcinoma, 43% had squamous cell lung cancer, 76% were ECOG PS 1.
Patients in both treatment arms received a median of 6 cycles of treatment. The following common (≥ 10% incidence) adverse reactions were observed at a similar incidence in ABRAXANE plus carboplatin-treated and paclitaxel injection plus carboplatin-treated patients: alopecia 56%, nausea 27%, fatigue 25%, decreased appetite 17%, asthenia 16%, constipation 16%, diarrhea 15%, vomiting 12%, dyspnea 12%, and rash 10% (incidence rates are for the ABRAXANE plus carboplatin treatment group).
Table 7 provides the frequency and severity of laboratory-detected abnormalities which occurred with a difference of ≥ 5% for all grades (1-4) or ≥ 2% for Grade 3-4 toxicity between ABRAXANE plus carboplatin-treated patients or paclitaxel injection plus carboplatin-treated patients. Table 7: Selected Hematologic Laboratory-Detected Abnormalities with a Difference of ≥ 5% for grades (1-4) or ≥ 2% for Grade 3-4 Toxicity Between Treatment Groups 1 508 patients assessed in ABRAXANE/carboplatin-treated group. 2 514 patients assessed in paclitaxel injection/carboplatin-treated group. 3 513 patients assessed in paclitaxel injection/carboplatin-treated group.
ABRAXANE (100 mg/m 2 weekly) plus carboplatin Paclitaxel Injection (200 mg/m 2 every 3 weeks) plus carboplatin Grades 1-4 (%) Grade 3-4 (%) Grades 1-4 (%) Grade 3-4 (%) Anemia 1,2 98 28 91 7 Neutropenia 1,3 85 47 83 58 Thrombocytopenia 1,3 68 18 55 9 Table 8 provides the frequency and severity of adverse reactions, which occurred with a difference of ≥ 5% for all grades (1-4) or ≥ 2% for Grade 3-4 between either treatment group for the 514 ABRAXANE plus carboplatin-treated patients compared with the 524 patients who received paclitaxel injection plus carboplatin. Table 8: Selected Adverse Reactions with a Difference of ≥5% for All Grade Toxicity or ≥2% for Grade 3-4 Toxicity Between Treatment Groups a Peripheral neuropathy is defined by the MedDRA Version 14.0 SMQ neuropathy (broad scope).
System Organ Class Adverse Reaction ABRAXANE (100 mg/m 2 weekly) + carboplatin (N=514) Paclitaxel Injection (200 mg/m 2 every 3 weeks) + carboplatin (N=524) Grade 1-4 Toxicity (%) Grade 3-4 Toxicity (%) Grades 1-4 Toxicity (%) Grade 3-4 Toxicity (%) Nervous system disorders Peripheral neuropathy a 48 3 64 12 General disorders and administration site conditions Edema peripheral 10 0 4 <1 Respiratory thoracic and mediastinal disorders Epistaxis 7 0 2 0 Musculoskeletal and connective tissue disorders Arthralgia 13 <1 25 2 Myalgia 10 <1 19 2 For the ABRAXANE plus carboplatin treated group, 17/514 (3%) patients developed Grade 3 peripheral neuropathy and no patients developed Grade 4 peripheral neuropathy. Grade 3 neuropathy improved to Grade 1 or resolved in 10/17 patients (59%) following interruption or discontinuation of ABRAXANE.
Adenocarcinoma of the Pancreas Adverse reactions were assessed in 421 patients who received ABRAXANE plus gemcitabine and 402 patients who received gemcitabine for the first-line systemic treatment of metastatic adenocarcinoma of the pancreas in a multicenter, multinational, randomized, controlled, open-label trial. Patients received a median treatment duration of 3.9 months in the ABRAXANE/gemcitabine group and 2.8 months in the gemcitabine group.
For the treated population, the median relative dose intensity for gemcitabine was 75% in the ABRAXANE/gemcitabine group and 85% in the gemcitabine group. The median relative dose intensity of ABRAXANE was 81%. Table 9 provides the frequency and severity of laboratory-detected abnormalities which occurred at a higher incidence for Grades 1-4 (≥ 5%) or for Grade 3-4 (≥ 2%) toxicity in ABRAXANE plus gemcitabine-treated patients.
Table 9: Selected Hematologic Laboratory-Detected Abnormalities with a Higher Incidence (≥ 5% for Grades 1-4 or ≥ 2% for Grades 3-4 Events) in the ABRAXANE/Gemcitabine Arm a 405 patients assessed in ABRAXANE/gemcitabine-treated group. b 388 patients assessed in gemcitabine-treated group. c 404 patients assessed in ABRAXANE/gemcitabine-treated group. d Neutrophil growth factors were administered to 26% of patients in the ABRAXANE/gemcitabine group. ABRAXANE (125 mg/m 2 )/ Gemcitabine d Gemcitabine Grades 1-4 (%) Grade 3-4 (%) Grades 1-4 (%) Grade 3-4 (%) Neutropenia a,b 73 38 58 27 Thrombocytopenia b,c 74 13 70 9 Table 10 provides the frequency and severity of adverse reactions which occurred with a difference of ≥ 5% for all grades or ≥ 2% for Grade 3 or higher in the ABRAXANE plus gemcitabine-treated group compared to the gemcitabine group.
Table 10: Selected Adverse Reactions with a Higher Incidence (≥5% for All Grade Toxicity or ≥2% for Grade 3 or Higher Toxicity) in the ABRAXANE/Gemcitabine Arm a Peripheral neuropathy is defined by the MedDRA Version 15.0 Standard MedDRA Query neuropathy (broad scope). b Urinary tract infections includes the preferred terms of: urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, and urinary tract infection enterococcal. System Organ Class Adverse Reaction ABRAXANE (125 mg/m 2) and gemcitabine (N=421) Gemcitabine (N=402) All Grades Grade 3 or Higher All Grades Grade 3 or Higher General disorders and administration site conditions Fatigue 248 (59%) 77 (18%) 183 (46%) 37 (9%) Peripheral edema 194 (46%) 13 (3%) 122 (30%) 12 (3%) Pyrexia 171 (41%) 12 (3%) 114 (28%) 4 (1%) Asthenia 79 (19%) 29 (7%) 54 (13%) 17 (4%) Mucositis 42 (10%) 6 (1%) 16 (4%) 1 (<1%) Gastrointestinal disorders Nausea 228 (54%) 27 (6%) 192 (48%) 14 (3%) Diarrhea 184 (44%) 26 (6%) 95 (24%) 6 (1%) Vomiting 151 (36%) 25 (6%) 113 (28%) 15 (4%) Skin and subcutaneous tissue disorders Alopecia 212 (50%) 6 (1%) 21 (5%) 0 Rash 128 (30%) 8 (2%) 45 (11%) 2 (<1%) Nervous system disorders Peripheral neuropathy a 227 (54%) 70 (17%) 51 (13%) 3 (1%) Dysgeusia 68 (16%) 0 33 (8%) 0 Headache 60 (14%) 1 (<1%) 38 (9%) 1 (<1%) Metabolism and nutrition disorders Decreased appetite 152 (36%) 23 (5%) 104 (26%) 8 (2%) Dehydration 87 (21%) 31 (7%) 45 (11%) 10 (2%) Hypokalemia 52 (12%) 18 (4%) 28 (7%) 6 (1%) Respiratory, thoracic and mediastinal disorders Cough 72 (17%) 0 30 (7%) 0 Epistaxis 64 (15%) 1 (<1%) 14 (3%) 1 (<1%) Infections and infestations Urinary tract infections b 47 (11%) 10 (2%) 20 (5%) 1 (<1%) Musculoskeletal and connective tissue disorders Pain in extremity 48 (11%) 3 (1%) 24 (6%) 3 (1%) Arthralgia 47 (11%) 3 (1%) 13 (3%) 1 (<1%) Myalgia 44 (10%) 4 (1%) 15 (4%) 0 Psychiatric disorders Depression 51 (12%) 1 (<1%) 24 (6%) 0 Additional clinically relevant adverse reactions that were reported in < 10% of the patients with adenocarcinoma of the pancreas who received ABRAXANE/gemcitabine included: Infections & infestations: oral candidiasis, pneumonia Vascular disorders: hypertension Cardiac disorders: tachycardia, congestive cardiac failure Eye disorders: cystoid macular edema Peripheral Neuropathy Grade 3 peripheral neuropathy occurred in 17% of patients who received ABRAXANE/gemcitabine compared to 1% of patients who received gemcitabine only; no patients developed Grade 4 peripheral neuropathy.
The median time to first occurrence of Grade 3 peripheral neuropathy in the ABRAXANE arm was 140 days. Upon suspension of ABRAXANE dosing, the median time to improvement from Grade 3 peripheral neuropathy to ≤ Grade 1 was 29 days. Of ABRAXANE-treated patients with Grade 3 peripheral neuropathy, 44% resumed ABRAXANE at a reduced dose.
Sepsis Sepsis occurred in 5% of patients who received ABRAXANE/gemcitabine compared to 2% of patients who received gemcitabine alone. Sepsis occurred both in patients with and without neutropenia. Risk factors for sepsis included biliary obstruction or presence of biliary stent. Pneumonitis Pneumonitis occurred in 4% of patients who received ABRAXANE/gemcitabine compared to 1% of patients who received gemcitabine alone.
Two of 17 patients in the ABRAXANE arm with pneumonitis died.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ABRAXANE or with paclitaxel injection and may be expected to occur with ABRAXANE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypersensitivity Reactions Severe and sometimes fatal hypersensitivity reactions. Cross-hypersensitivity between ABRAXANE and other taxanes has been reported. Cardiovascular Congestive heart failure, left ventricular dysfunction, and atrioventricular block. Most patients were previously exposed to cardiotoxic drugs, such as anthracyclines, or had underlying cardiac history.
Respiratory Pneumonitis, interstitial pneumonia, and pulmonary embolism Radiation pneumonitis in patients receiving concurrent radiotherapy. Lung fibrosis has been reported with paclitaxel injection. Neurologic Cranial nerve palsies and vocal cord paresis, as well as autonomic neuropathy resulting in paralytic ileus. Vision Disorders Reduced visual acuity due to cystoid macular edema (CME).
After cessation of treatment, CME may improve, and visual acuity may return to baseline. Abnormal visual evoked potentials in patients treated with paclitaxel injection suggest persistent optic nerve damage. Hepatic Hepatic necrosis and hepatic encephalopathy leading to death in patients treated with paclitaxel injection.
Gastrointestinal (GI) Intestinal obstruction, intestinal perforation, pancreatitis, and ischemic colitis. In patients treated with paclitaxel injection, neutropenic enterocolitis (typhlitis) despite the coadministration of G-CSF, alone and in combination with other chemotherapeutic agents. Injection Site Reaction Extravasation.
Closely monitor the ABRAXANE infusion site for possible infiltration during drug administration [see Dosage and Administration 2.1)]. Severe events such as phlebitis, cellulitis, induration, necrosis, and fibrosis have been reported with paclitaxel injection. In some cases, the onset of the injection site reaction occurred during a prolonged infusion or was delayed up to ten days.
Recurrence of skin reactions at a site of previous extravasation following administration of paclitaxel injection at a different site has been reported. Metabolic and Nutritional Disorders Tumor lysis syndrome Other Clinical Events Skin reactions including generalized or maculopapular rash, erythema, and pruritus. Photosensitivity reactions, radiation recall phenomenon, scleroderma, and in some patients previously exposed to capecitabine, reports of palmar-plantar erythrodysesthesia.
Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Conjunctivitis, cellulitis, and increased lacrimation have been reported with paclitaxel injection. Accidental Exposure Upon inhalation of paclitaxel, dyspnea, chest pain, burning eyes, sore throat, and nausea have been reported. Following topical exposure, tingling, burning, and redness have been reported.
Adverse reaction frequency tables (US label) US FDA label
| a Paclitaxel injection patients received premedication. b Includes treatment-related events related to hypersensitivity (e.g., flushing, dyspnea, chest pain, hypotension) that began on a day of dosing. c Severe events are defined as at least Grade 3 toxicity. | ||
| Percent of Patients | ||
| ABRAXANE 260 mg/m2 over 30 min (n=229) | Paclitaxel Injection 175 mg/m2 over 3 ha (n=225) | |
| Bone Marrow | ||
| Neutropenia | ||
| < 2.0 x 109/L | 80 | 82 |
| < 0.5 x 109/L | 9 | 22 |
| Thrombocytopenia | ||
| < 100 x 109/L | 2 | 3 |
| < 50 x 109/L | <1 | <1 |
| Anemia | ||
| < 11 g/dL | 33 | 25 |
| < 8 g/dL | 1 | <1 |
| Infections | 24 | 20 |
| Febrile Neutropenia | 2 | 1 |
| Neutropenic Sepsis | <1 | <1 |
| Bleeding | 2 | 2 |
| Hypersensitivity Reactionb | ||
| All | 4 | 12 |
| Severec | 0 | 2 |
| Cardiovascular | ||
| Vital Sign Changes During Administration | ||
| Bradycardia | <1 | <1 |
| Hypotension | 5 | 5 |
| Severe Cardiovascular Eventsc | 3 | 4 |
| Abnormal ECG | ||
| All Patients | 60 | 52 |
| Patients with Normal Baseline | 35 | 30 |
| Respiratory | ||
| Cough | 7 | 6 |
| Dyspnea | 12 | 9 |
| Sensory Neuropathy | ||
| Any Symptoms | 71 | 56 |
| Severe Symptomsc | 10 | 2 |
| Myalgia / Arthralgia | ||
| Any Symptoms | 44 | 49 |
| Severe Symptomsc | 8 | 4 |
| Asthenia | ||
| Any Symptoms | 47 | 39 |
| Severe Symptomsc | 8 | 3 |
| Fluid Retention/Edema | ||
| Any Symptoms | 10 | 8 |
| Severe Symptomsc | 0 | <1 |
| Gastrointestinal | ||
| Nausea | ||
| Any Symptoms | 30 | 22 |
| Severe Symptomsc | 3 | <1 |
| Vomiting | ||
| Any Symptoms | 18 | 10 |
| Severe Symptomsc | 4 | 1 |
| Diarrhea | ||
| Any Symptoms | 27 | 15 |
| Severe Symptomsc | <1 | 1 |
| Mucositis | ||
| Any Symptoms | 7 | 6 |
| Severe Symptomsc | <1 | 0 |
| Alopecia | 90 | 94 |
| Hepatic (Patients with Normal Baseline) | ||
| Bilirubin Elevations | 7 | 7 |
| Alkaline Phosphatase Elevations | 36 | 31 |
| AST (SGOT) Elevations | 39 | 32 |
| Injection Site Reaction | <1 | 1 |
| 1 508 patients assessed in ABRAXANE/carboplatin-treated group. 2 514 patients assessed in paclitaxel injection/carboplatin-treated group. 3 513 patients assessed in paclitaxel injection/carboplatin-treated group. | ||||
| ABRAXANE (100 mg/m2 weekly) plus carboplatin | Paclitaxel Injection (200 mg/m2 every 3 weeks) plus carboplatin | |||
| Grades 1-4 (%) | Grade 3-4 (%) | Grades 1-4 (%) | Grade 3-4 (%) | |
| Anemia1,2 | 98 | 28 | 91 | 7 |
| Neutropenia1,3 | 85 | 47 | 83 | 58 |
| Thrombocytopenia1,3 | 68 | 18 | 55 | 9 |
| a Peripheral neuropathy is defined by the MedDRA Version 14.0 SMQ neuropathy (broad scope). | |||||
| System Organ Class | Adverse Reaction | ABRAXANE (100 mg/m2 weekly) + carboplatin (N=514) | Paclitaxel Injection (200 mg/m2 every 3 weeks) + carboplatin (N=524) | ||
| Grade 1-4 Toxicity (%) | Grade 3-4 Toxicity (%) | Grades 1-4 Toxicity (%) | Grade 3-4 Toxicity (%) | ||
| Nervous system disorders | Peripheral neuropathya | 48 | 3 | 64 | 12 |
| General disorders and administration site conditions | Edema peripheral | 10 | 0 | 4 | <1 |
| Respiratory thoracic and mediastinal disorders | Epistaxis | 7 | 0 | 2 | 0 |
| Musculoskeletal and connective tissue disorders | Arthralgia | 13 | <1 | 25 | 2 |
| Myalgia | 10 | <1 | 19 | 2 | |
| a 405 patients assessed in ABRAXANE/gemcitabine-treated group. b 388 patients assessed in gemcitabine-treated group. c 404 patients assessed in ABRAXANE/gemcitabine-treated group. d Neutrophil growth factors were administered to 26% of patients in the ABRAXANE/gemcitabine group. | ||||
| ABRAXANE (125 mg/m2)/ Gemcitabined | Gemcitabine | |||
| Grades 1-4 (%) | Grade 3-4 (%) | Grades 1-4 (%) | Grade 3-4 (%) | |
| Neutropeniaa,b | 73 | 38 | 58 | 27 |
| Thrombocytopeniab,c | 74 | 13 | 70 | 9 |
| a Peripheral neuropathy is defined by the MedDRA Version 15.0 Standard MedDRA Query neuropathy (broad scope). b Urinary tract infections includes the preferred terms of: urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, and urinary tract infection enterococcal. | |||||
| System Organ Class | Adverse Reaction | ABRAXANE (125 mg/m2) and gemcitabine (N=421) | Gemcitabine (N=402) | ||
| All Grades | Grade 3 or Higher | All Grades | Grade 3 or Higher | ||
| General disorders and administration site conditions | Fatigue | 248 (59%) | 77 (18%) | 183 (46%) | 37 (9%) |
| Peripheral edema | 194 (46%) | 13 (3%) | 122 (30%) | 12 (3%) | |
| Pyrexia | 171 (41%) | 12 (3%) | 114 (28%) | 4 (1%) | |
| Asthenia | 79 (19%) | 29 (7%) | 54 (13%) | 17 (4%) | |
| Mucositis | 42 (10%) | 6 (1%) | 16 (4%) | 1 (<1%) | |
| Gastrointestinal disorders | Nausea | 228 (54%) | 27 (6%) | 192 (48%) | 14 (3%) |
| Diarrhea | 184 (44%) | 26 (6%) | 95 (24%) | 6 (1%) | |
| Vomiting | 151 (36%) | 25 (6%) | 113 (28%) | 15 (4%) | |
| Skin and subcutaneous tissue disorders | Alopecia | 212 (50%) | 6 (1%) | 21 (5%) | 0 |
| Rash | 128 (30%) | 8 (2%) | 45 (11%) | 2 (<1%) | |
| Nervous system disorders | Peripheral neuropathya | 227 (54%) | 70 (17%) | 51 (13%) | 3 (1%) |
| Dysgeusia | 68 (16%) | 0 | 33 (8%) | 0 | |
| Headache | 60 (14%) | 1 (<1%) | 38 (9%) | 1 (<1%) | |
| Metabolism and nutrition disorders | Decreased appetite | 152 (36%) | 23 (5%) | 104 (26%) | 8 (2%) |
| Dehydration | 87 (21%) | 31 (7%) | 45 (11%) | 10 (2%) | |
| Hypokalemia | 52 (12%) | 18 (4%) | 28 (7%) | 6 (1%) | |
| Respiratory, thoracic and mediastinal disorders | Cough | 72 (17%) | 0 | 30 (7%) | 0 |
| Epistaxis | 64 (15%) | 1 (<1%) | 14 (3%) | 1 (<1%) | |
| Infections and infestations | Urinary tract infections b | 47 (11%) | 10 (2%) | 20 (5%) | 1 (<1%) |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 48 (11%) | 3 (1%) | 24 (6%) | 3 (1%) |
| Arthralgia | 47 (11%) | 3 (1%) | 13 (3%) | 1 (<1%) | |
| Myalgia | 44 (10%) | 4 (1%) | 15 (4%) | 0 | |
| Psychiatric disorders | Depression | 51 (12%) | 1 (<1%) | 24 (6%) | 0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on its mechanism of action and findings in animals, ABRAXANE can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available human data on ABRAXANE use in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity at doses approximately 2% of the daily maximum recommended human dose on a mg/m 2 basis (see Data).
Advise females of reproductive potential of the potential risk to a fetus. The background rate of major birth defects and miscarriage is unknown for the indicated population. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal Data In embryo-fetal development studies, intravenous administration of paclitaxel formulated as albumin-bound particles to rats during pregnancy, on gestation days 7 to 17 at doses of 6 mg/m 2 (approximately 2% of the daily maximum recommended human dose on a mg/m 2 basis) caused embryo-fetal toxicities, as indicated by intrauterine mortality, increased resorptions (up to 5-fold), reduced numbers of litters and live fetuses, reduction in fetal body weight, and increase in fetal anomalies. Fetal anomalies included soft tissue and skeletal malformations, such as eye bulge, folded retina, microphthalmia, and dilation of brain ventricles.
Mechanism of action
12.1 Mechanism of Action ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
US FDA labelPharmacokinetics
Elimination At the clinical dose range of 80 to 300 mg/m 2 (0.31 to 1.15 times the maximum approved recommended dosage), the mean total clearance of paclitaxel ranges from 13 to 30 L/h/m 2 and the mean terminal half-life ranges from 13 to 27 hours.
Excretion After a 30-minute infusion of 260 mg/m 2 doses of ABRAXANE, the mean values for cumulative urinary recovery of unchanged drug (4%) indicated extensive non-renal clearance.
Less than 1% of the total administered dose was excreted in urine as the metabolites 6α-hydroxypaclitaxel and 3'- p -hydroxypaclitaxel.
Fecal excretion was approximately 20% of the total dose administered.
The observed mean AUC inf of free carboplatin was approximately 23% higher than the targeted value (6 min*mg/mL), but its mean half-life and clearance were consistent with those reported in the absence of paclitaxel.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The pharmacokinetics of total paclitaxel following 30- and 180-minute infusions of ABRAXANE at dose levels of 80 to 375 mg/m 2 (0.31 to 1.15 times the maximum approved recommended dosage) were determined in clinical studies. Dose levels of mg/m 2 refer to mg of paclitaxel in ABRAXANE. Following intravenous administration of ABRAXANE to patients with solid tumors, paclitaxel plasma concentrations declined in a biphasic manner, the initial rapid decline representing distribution to the peripheral compartment and the slower second phase representing drug elimination.
Following ABRAXANE infusion, paclitaxel exhibited linear drug exposure (AUC) across clinical doses ranging from 80 to 300 mg/m 2 (0.31 to 1.15 times the maximum approved recommended dosage). The pharmacokinetics of paclitaxel in ABRAXANE were independent of the duration of intravenous administration. The pharmacokinetic data of 260 mg/m 2 ABRAXANE administered over a 30-minute infusion was compared to the pharmacokinetics of 175 mg/m 2 paclitaxel injection over a 3-hour infusion.
Clearance was larger (43%) and the volume of distribution was higher (53%) for ABRAXANE than for paclitaxel injection. There were no differences in terminal half-lives. Distribution Following ABRAXANE administration to patients with solid tumors, paclitaxel is evenly distributed into blood cells and plasma and is highly bound to plasma proteins (94%).
The total volume of distribution is approximately 1741 L; the large volume of distribution indicates extensive extravascular distribution and/or tissue binding of paclitaxel. In a within-patient comparison study, the fraction of unbound paclitaxel in plasma was significantly higher with ABRAXANE (6.2%) than with solvent-based paclitaxel (2.3%).
This contributes to significantly higher exposure to unbound paclitaxel with ABRAXANE compared with solvent-based paclitaxel, when the total exposure is comparable. In vitro studies of binding to human serum proteins, using paclitaxel concentrations ranging from 0.1 to 50 µg/mL, indicated that the presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.
Elimination At the clinical dose range of 80 to 300 mg/m 2 (0.31 to 1.15 times the maximum approved recommended dosage), the mean total clearance of paclitaxel ranges from 13 to 30 L/h/m 2 and the mean terminal half-life ranges from 13 to 27 hours. Metabolism In vitro studies with human liver microsomes and tissue slices showed that paclitaxel in ABRAXANE was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'- p -hydroxypaclitaxel and 6α, 3'- p -dihydroxypaclitaxel, by CYP3A4.
In vitro, the metabolism of paclitaxel to 6α-hydroxypaclitaxel was inhibited by a number of agents (ketoconazole, verapamil, diazepam, quinidine, dexamethasone, cyclosporin, teniposide, etoposide, and vincristine), but the concentrations used exceeded those found in vivo following normal therapeutic doses. Testosterone, 17α-ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of CYP2C8, also inhibited the formation of 6α-hydroxypaclitaxel in vitro.
The pharmacokinetics of paclitaxel may also be altered in vivo as a result of interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 and/or CYP3A4 [see Drug Interactions (7)]. Excretion After a 30-minute infusion of 260 mg/m 2 doses of ABRAXANE, the mean values for cumulative urinary recovery of unchanged drug (4%) indicated extensive non-renal clearance.
Less than 1% of the total administered dose was excreted in urine as the metabolites 6α-hydroxypaclitaxel and 3'- p -hydroxypaclitaxel. Fecal excretion was approximately 20% of the total dose administered. Specific Populations No clinically meaningful differences in the pharmacokinetics of paclitaxel in ABRAXANE were observed based on body weight (40 to 143 kg), body surface area (1.3 to 2.4 m²), sex, race (Asian vs.
White), age (24 to 85 years), type of solid tumors, mild to moderate renal impairment (creatinine clearance 30 to <90 mL/min), and mild hepatic impairment (total bilirubin >1 to ≤1.5 x ULN and AST ≤10 x ULN). Patients with moderate (total bilirubin >1.5 to 3 x ULN and AST ≤10 x ULN) or severe (total bilirubin >3 to 5 x ULN) hepatic impairment had a 22% to 26% decrease in the maximum elimination rate of paclitaxel and approximately 20% increase in mean paclitaxel AUC compared with patients with normal hepatic function (total bilirubin ≤ULN and AST ≤ULN) [see Dosage and Administration (2.5) and Use in Specific Populations (8.7)].
The effect of severe renal impairment or end stage renal disease (creatinine clearance < 30 mL/min) on the pharmacokinetics of paclitaxel in ABRAXANE is unknown. Drug Interaction Studies Carboplatin: Administration of carboplatin immediately after the completion of the ABRAXANE infusion to patients with NSCLC did not cause clinically meaningful changes in paclitaxel exposure.
The observed mean AUC inf of free carboplatin was approximately 23% higher than the targeted value (6 min*mg/mL), but its mean half-life and clearance were consistent with those reported in the absence of paclitaxel.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Paclitaxel 6 mg/mL, 17 mL Vial | ₱922.22–₱1,957.00Reference ₱1,375.90 | per vial | DPRI procurement range |
| Paclitaxel 6 mg/mL, 25 mL Vial | ₱1,900.00–₱5,880.00Reference ₱3,248.00 | per vial | DPRI procurement range |
| Paclitaxel 6 mg/mL, 43.4 mL Vial | ₱3,250.00–₱5,100.00Reference ₱4,000.00 | per vial | DPRI procurement range |
| Paclitaxel 6 mg/mL, 5 mL Vial | ₱447.24–₱995.00Reference ₱488.00 | per vial | DPRI procurement range |
| Paclitaxel 6 mg/mL, 16.7 mL vial | ₱980.00 | per vial | DPRI reference price |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Paclitaxel |
| PNF listing | Inj.: 6 mg/mL, 5 mL, 16.7 mL, 17 mL, 25 mL and 43.4 mL vial (IV, IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ABRAXANE · Abraxis BioScience, LLC [US FDA-approved label, version 37, October 31, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
